Vascular Smooth Muscle–Specific NLRP3 Hyperactivation Drives Arterial Intimal Hyperplasia in Mice

Vascular Smooth Muscle–Specific NLRP3 Hyperactivation Drives Arterial Intimal Hyperplasia in Mice | Research Square window.SnipcartSettings = { analytics: { enabled: false } }; (function() { var accessVector = localStorage.getItem('access_vector') || ''; window.dataLayer = window.dataLayer || []; if (accessVector) { window.dataLayer.push({ user: { profile: { profileInfo: { snid: accessVector } } } }); } })(); (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src='https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);})(window,document,'script','dataLayer','GTM-K279D39R'); Browse Preprints In Review Journals COVID-19 Preprints AJE Video Bytes Research Tools Research Promotion AJE Professional Editing AJE Rubriq About Preprint Platform In Review Editorial Policies Our Team Advisory Board Help Center Sign In Submit a Preprint Cite Share Download PDF Research Article Vascular Smooth Muscle–Specific NLRP3 Hyperactivation Drives Arterial Intimal Hyperplasia in Mice Yun-Ting Wang, Alexandra K Moura, Rui Zuo, Wei Gao, Bradley K McConnell, and 4 more This is a preprint; it has not been peer reviewed by a journal. https://doi.org/ 10.21203/rs.3.rs-8734377/v1 This work is licensed under a CC BY 4.0 License Status: Under Revision Version 1 posted 5 You are reading this latest preprint version Abstract Intimal hyperplasia is a major contributor to restenosis after vascular interventions and to atherosclerotic lesion progression, driven largely by vascular smooth muscle cell (VSMC) inflammatory activation, phenotypic switching, and maladaptive remodeling. While NOD-like receptor pyrin domain 3 (NLRP3) inflammasome activity has been linked to vascular diseases, direct evidence that VSMC-intrinsic NLRP3 hyperactivation drives VSMC dysfunction and intimal hyperplasia in vivo has been lacking. Here, we generated a VSMC-specific Nlrp3 knock-in mouse ( Nlrp3 L351P/+/Myh11−Cre , “ Nlrp3 SMKI ”) and subjected it to carotid partial ligation under hypercholesterolemic conditions. VSMC Nlrp3 gain-of-function knock-in induced robust caspase-1 activation in vivo, including in unligated arteries, and markedly amplified injury-triggered inflammasome activation. Nlrp3 SMKI arteries exhibited heightened vascular inflammation (VCAM-1 upregulation and increased macrophage accumulation), enhanced activation of Gasdermin D (GSDMD) with increased cell death, and greater VSMC proliferative/migratory remodeling. These changes translated into significantly worsened neointimal lesion growth (increased intimal area and intima-to-media ratio). Interestingly, VSMC Nlrp3 gain-of-function accelerated vascular injury-induced lipid loading and VSMC-to-foam cell-like transition. Mechanistically, these pathological responses were accompanied by suppression of the transcription factor EB (TFEB) and broad impairment of lysosome–autophagy homeostasis, supporting TFEB-dependent lysosome–autophagy quality control as a central protective node that restrains not only lipid accumulation and foam cell transition, but also inflammatory activation, cell death, and proliferative/migratory remodeling during vascular injury. Collectively, these data provide the first direct evidence that VSMC NLRP3 hyperactivation drives VSMC dysfunction, intimal hyperplasia, and foam cell–like phenotypic switching, highlighting VSMC NLRP3–TFEB signaling as a highly translational therapeutic axis to limit restenosis and plaque progression. VSMC NLRP3 inflammasome GSDMD TFEB lysosome–autophagy intimal hyperplasia Figures Figure 1 Figure 2 Figure 3 Figure 4 Figure 5 Figure 6 Figure 7 Introduction Intimal hyperplasia is a major pathological driver of restenosis after vascular interventions and contributes to lumen narrowing during atherosclerotic disease progression 1 , 2 . Despite improvements in stent design and adjunct pharmacotherapy, neointimal lesion formation remains a common and clinically significant obstacle 3 . At the tissue level, intimal hyperplasia reflects a coordinated response to vascular injury and disturbed flow, involving inflammatory activation of the vessel wall, recruitment of leukocytes, and remodeling of extracellular matrix that collectively promote neointimal growth 4 . Defining the cell-intrinsic mechanisms that amplify this maladaptive remodeling program is essential for developing more precise, vessel wall–directed therapies. Vascular smooth muscle cells (VSMCs) are central effectors of intimal hyperplasia. Following injury, VSMCs undergo phenotypic switching from a contractile to a synthetic state, characterized by enhanced proliferation, migration into the intima, and secretion of remodeling factors, such as matrix metalloproteinases 1 , 5 , 6 . This plasticity is strongly influenced by inflammatory cues and cell stress, which can create feed-forward loops that perpetuate VSMC dysfunction and accelerate lesion progression 7 . Beyond classical neointimal expansion, growing evidence from lineage-tracing and single-cell studies indicates that VSMCs can adopt macrophage-like gene programs and contribute substantially to foam cell populations in mouse and human atherosclerotic plaques 8 , 9 . Thus, VSMC maladaptation encompasses not only proliferative/migratory remodeling but also lipid-driven phenotypic transitions that can worsen lesion burden and complexity. Inflammasomes are innate immune signaling platforms that couple cellular stress sensing to inflammatory effector outputs 10 . Among them, the NLRP3 inflammasome is activated by diverse vascular disease–relevant stimuli, including oxidative stress, and lipid-associated danger signals 11 – 13 . Upon activation, NLRP3 promotes caspase-1 activation, which drives the maturation of IL-1β/IL-18 and the cleavage of GSDMD, leading to pore formation, the release of inflammatory mediators, and pyroptosis-associated cell injury 14 , 15 . Consistent with these functions, NLRP3 pathway activation has been implicated in atherosclerosis and post-injury vascular remodeling 16 – 18 . However, the vascular wall contains multiple potential cellular sources of NLRP3 activity, including infiltrating immune cells, endothelial cells, and VSMCs, making it difficult to determine whether NLRP3 signaling in VSMCs is sufficient to initiate and sustain the remodeling cascade culminating in intimal hyperplasia and lipid-laden VSMC phenotypes. Our recent work showed that carotid partial ligation injury under hypercholesterolemic conditions activates the NLRP3 inflammasome in VSMCs and that global Nlrp3 deficiency attenuates injury-induced inflammasome activation and intimal hyperplasia 18 . While these findings support a causal role for NLRP3 signaling in vascular remodeling, global loss-of-function approaches cannot distinguish the relative contributions of hematopoietic versus vessel wall–resident compartments, nor can they directly establish the sufficiency of VSMC-intrinsic NLRP3 activation in driving VSMC dysfunction in vivo 18 . This knowledge gap is highly relevant to translational strategy: if VSMC-intrinsic NLRP3 hyperactivation is sufficient to amplify inflammation, pyroptosis-associated injury, and proliferative/migratory remodeling, then targeting NLRP3 signaling specifically within VSMCs could represent a focused therapeutic avenue to limit neointimal growth while reducing systemic immune perturbation. Here, we directly test the VSMC-intrinsic contribution of NLRP3 by generating a VSMC-specific Nlrp3 gain-of-function model. We crossed Nlrp3 L351PneoR mice with Myh11-Cre to create Nlrp3 L351P/+/Myh11−Cre mice ( Nlrp3 SMKI ) and littermate controls, leveraging a gain-of-function NLRP3 substitution analogous to a human cryopyrin-associated periodic syndromes (CAPS)-associated mutation that enhances inflammasome activation 19 . Using carotid partial ligation combined with a Paigen diet to induce hypercholesterolemia-associated remodeling 20 , we assessed inflammasome activation, vascular inflammation, GSDMD-linked cell injury, VSMC proliferation and migration, neointimal lesion growth, and lipid accumulation associated with VSMC-to–foam cell–like transition in vivo. This approach provides direct mechanistic evidence for how VSMC-intrinsic NLRP3 hyperactivation programs maladaptive vascular remodeling and identifies VSMC NLRP3 signaling as a translationally actionable target to treat intimal hyperplasia and VSMC-driven foam cell transition. Materials and Methods Antibodies and reagents Primary antibodies: NLRP3 (Biotechne MAB7578), cleaved-caspase1 (Affinity AF4005), FITC-α-SMA (Sigma F3777), Cy3-αSMA (Sigma C6198), VCAM1 (Abcam ab134047), F4/80 (BD 565411), CD206 (CST 24595), GSDMD (Sigma G7422), Ki67 (Abcam ab16667), MMP2 (Abcam ab92536), PLIN2 (Proteintech 15294-1-AP), TFEB (Bethyl Laboratories A303-673A), LAMP2A (Abcam ab18528), LAMP1 (BD 553792), LC3 (CST 12741S). Secondary antibody for immunofluorescence (1:500 dilution): Donkey anti-Mice IgG (H + L) Secondary Antibody, Alexa Fluor® 488 conjugate (Thermo Fisher A-21202); Donkey anti-Rabbit IgG (H + L) Secondary Antibody, Alexa Fluor® 488 conjugate (Thermo Fisher A21206); Donkey anti-Mice IgG (H + L) Secondary Antibody, Alexa Fluor® 555 conjugate (Thermo Fisher A-31570); Donkey anti-Rabbit IgG (H + L) Secondary Antibody, Alexa Fluor® 555 conjugate (Thermo Fisher A-31572); Donkey anti-Rat IgG (H + L) Highly Cross-Adsorbed, Alexa Fluor 594 (Thermo Fisher A21209); Donkey anti-Rabbit IgG (H + L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor™ Plus 647 (Thermo Fisher A32795TR); Donkey anti-Rat IgG (H + L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor™ 647 (Thermo Fisher A78947). Reagents: Green FLICA Caspase-1 Assay Kit (Immunochemistry Technologies #98), In Situ Cell Death Detection Kit (Sigma 11684795910), Sirius Red (Sigma 365548-5g), Fast green (Sigma F7252-5g), Hematoxylin and Eosin staining kit (Teomics HAE- 1), Oil red O (VWR 135140-100G), Bodipy (Thermo Fisher D3922). Mice All procedures involving animals were conducted in accordance with protocols approved by the University of Houston Institutional Review Board (IRB) and Institutional Animal Care and Use Committee (IACUC). Mice were maintained in a specific pathogen-free, temperature-regulated animal facility on a 12 h light/12 h dark schedule, with free access to water and a standard chow diet (PicoLab® Rodent Diet 20; 5053) unless noted otherwise. Generation of VSMC-specific Nlrp3 Knock-in mice Nlrp3 L351PneoR mice (JAX:017970) harbor a Cre-conditional Nlrp3 L351P allele in the absence of Cre; the neoR cassette disrupts Nlrp3 expression, whereas Cre-mediated recombination restores expression of an Nlrp3 transcript carrying the L351P mutation in Cre-specific tissues. Myh11-Cre transgenic mice (JAX:007742) were obtained from The Jackson Laboratory. To generate a VSMC-specific gain-of-function (GOF) model, Nlrp3 L351PneoR mice were crossed with Myh11-Cre mice to produce Nlrp3 L351P/+/Myh11−Cre ( Nlrp3 SMKI ) mice and Cre-negative littermate Nlrp3 L351P/+/WT ( Nlrp3 ctrl ) controls. Both Nlrp3 SMKI and littermate control Nlrp3 ctrl mice were heterozygous for the Nlrp3 L351P/+ allele. Genotypes were confirmed by PCR using primers and conditions provided by the vendor. Partial carotid ligation surgery Partial carotid ligation was performed in 6-month-old male Nlrp3 SMKI mice and Nlrp3 ctrl littermates. The left carotid artery was subjected to partial ligation, while the right side remained unligated and was used as the control vessel 18 , 20 , 21 . Following surgery, mice were maintained on a Paigen’s diet (Research Diets, D12336) containing 35% kcal from fat and 1.25% cholesterol for 4 weeks. Mice were anesthetized and euthanized by cervical dislocation, and bilateral carotid arteries were excised for immunohistochemistry and immunofluorescence. Tissues were embedded in Tissue-Tek O.C.T., snap-frozen in liquid nitrogen, stored at − 80°C, and cryosectioned at 8 µm. Immunofluorescence staining Frozen sections were briefly equilibrated at room temperature and air-dried for no longer than 15 min. Sections were then fixed in freshly prepared 4% paraformaldehyde for 15 min at room temperature, followed by rinsing in PBS. For simultaneous permeabilization and blocking, sections were incubated for 1 h at room temperature in PBS containing 5% BSA and 0.3% Triton X-100. Primary antibodies (as indicated) were applied and incubated overnight at 4°C. After washing, sections were incubated with species-matched Alexa Fluor–conjugated secondary antibodies (488/555/647) for 1 h at room temperature. Nuclei were counterstained with DAPI for 15 min and slides were mounted using an antifade mounting medium. Fluorescence images were acquired using an Olympus IX73 imaging system under identical exposure and acquisition parameters across groups. Quantification was performed in Image-Pro Plus 6.0 by measuring mean fluorescence density (as applicable) or calculating Pearson’s correlation coefficient (PCC) for protein colocalization within the carotid intima and media. For each carotid artery, three consecutive serial sections were stained and analyzed for each marker, and values from the three sections were averaged to generate a single measurement per animal. For regional analysis, unligated arteries were quantified in the medial layer only, identified as the continuous α-SMA–positive band. In ligated arteries, α-SMA–positive VSMCs in both the neointima (migrated VSMCs) and the media were included. Specificity was assessed using adjacent sections incubated with matched isotype IgG at the same concentration in place of primary antibodies; no appreciable nonspecific background signal was detected. Potential elastin autofluorescence in the AF488 channel under low-signal conditions was minimized by imaging α-SMA with strong FITC signals (≤ 50 ms exposure), while most targets were collected in the AF555 or AF647 channels, thereby avoiding interference from elastin-derived fluorescence 18 . FLICA analysis of caspase-1 activation Frozen sections were equilibrated to room temperature and air-dried for ≤ 15 min. Without fixation, sections were incubated with the FLICA reagent together with Hoechst 33342 (FLICA Assay Kit) for 1.5 h at 37°C. Slides were then washed three times in pre-warmed assay buffer (10 min each, 37°C). The FLICA-derived green fluorescence was captured using an Olympus IX73 imaging system 18 , 22 . TUNEL staining Frozen tissue sections were fixed with freshly prepared 4% paraformaldehyde for 20 min at room temperature, followed by washing in PBS for 30 min. Sections were then permeabilized in 0.1% Triton X-100/0.1% sodium citrate for 2 min on ice. TUNEL reaction mixture was freshly prepared and 50 µL was applied to each section, followed by incubation for 60 min at 37°C in a humidified chamber protected from light; negative controls were incubated with Label Solution lacking enzyme. After incubation, slides were rinsed three times with PBS and imaged by fluorescence microscopy using FITC settings (Ex 450–500 nm; Em 515–565 nm) 18 . Sirius red and fast green staining Frozen sections were fixed in Kahle’s fixative for 15 min at room temperature, rinsed with PBS, and stained for 60 min at room temperature in a picric acid–based Sirius Red/Fast Green solution (0.1% Sirius Red and 0.1% Fast Green in saturated aqueous picric acid). Slides were then rinsed twice in acidified water (0.1 N HCl in ddH₂O; 1 min each). Sections were dehydrated through two changes of 100% ethanol and cleared in xylene prior to coverslipping with mounting medium. Images were acquired immediately using an Olympus IX73 imaging system 23 . H&E staining Hematoxylin and eosin staining was performed using a commercial kit (Teomics, HAE-1). Briefly, frozen sections were fixed in 4% paraformaldehyde for 15 min at room temperature and rinsed with distilled water. Sections were stained with Mayer’s hematoxylin for 5 min, washed twice in distilled water, and briefly blued using bluing reagent (10–15 s) followed by two additional water rinses. Slides were then dipped in absolute ethanol to remove residual water, counterstained with Eosin Y for 2–3 min and rinsed in absolute ethanol. After clearing, sections were mounted with synthetic resin and imaged on an Olympus IX73 microscope 18 , 23 . Oil red O staining Frozen sections (8 µm) were allowed to air-dry and fixed in 4% PFA for 15 min. Slides were then rinsed in distilled water (three changes) and immersed in distilled water for 20 min. To minimize aqueous carryover, sections briefly dipped in 60% isopropanol for 1 min prior to staining. Sections were incubated with freshly prepared Oil Red O working solution for 30 min, rinsed in 60% isopropanol for 2 min, and washed twice with distilled water. Slides were mounted with mounting medium and imaged immediately using an Olympus IX73 imaging system 22 , 23 . BODIPY 493/503 staining Neutral lipid droplets were visualized using BODIPY 493/503 (Invitrogen, D3922). Frozen sections were fixed in 4% paraformaldehyde for 10 min and rinsed with PBS-T. Sections were then incubated for 1 h at room temperature with BODIPY 493/503 (40 µg/mL) together with DAPI diluted in PBS-T. After washing in PBS-T, slides were mounted with Mowiol and imaged immediately using an Olympus IX73 imaging system 24 , 25 . Statistical analysis All quantitative results are reported as mean ± SEM. Given the small cohort sizes (N < 10) and the lack of normality in our datasets, nonparametric tests were applied throughout. Comparisons among three or more groups were performed using the Kruskal–Wallis test with Dunn’s post hoc multiple-comparisons correction. For two-group comparisons, the Mann–Whitney U test was used. Analyses were conducted in GraphPad Prism (version 9.0; GraphPad Software, USA). A two-sided P value < 0.05 was considered statistically significant. Sample sizes were selected based on prior publications and pilot data to provide adequate sensitivity for detecting biologically relevant effects. Data was excluded only for pre-specified reasons, including sample contamination, technical failure, or clear measurement artifacts; outliers were handled according to predefined criteria. Investigators were blinded to group assignment during experimental procedures and outcome quantification to reduce bias and ensure objective interpretation. Results VSMC-specific Nlrp3 gain-of-function mutation activates the NLRP3 inflammasome in vivo. In our recent work, we showed that carotid partial ligation injury under hypercholesterolemic conditions activates the NLRP3 inflammasome in VSMCs, and that global Nlrp3 deficiency attenuates injury-induced inflammasome activation and intimal hyperplasia 18 . To directly define the contribution of VSMC-intrinsic NLRP3 to pathological vascular remodeling, we generated a VSMC-specific Nlrp3 knock-in model by crossing Nlrp3 L351PneoR mice with Myh11-Cre mice, yielding Nlrp3 L351P/+/Myh11−Cre ( Nlrp3 SMKI ) mice and littermate Nlrp3 L351P/+/WT ( Nlrp3 ctrl ) controls (Fig. 1 A). The L351P substitution (from leucine to proline at residue 351) corresponds to the human L353P mutation associated with cryopyrin-associated periodic syndromes (CAPS) and is predicted to enhance NLRP3 inflammasome assembly/activation through altered interdomain or protein–protein interactions 19 . We subjected Nlrp3 SMKI and Nlrp3 ctrl mice to partial carotid ligation and Paigen’s diet to induce intimal hyperplasia 18 , 20 , 21 , then assessed inflammasome activation in ligated and contralateral unligated arteries. NLRP3 immunostaining was increased after ligation in both genotypes, and this injury-induced upregulation was significantly greater in Nlrp3 SMKI arteries; by contrast, NLRP3 levels were comparable between genotypes in unligated arteries (Fig. 1 B–C). Importantly, FLICA labeling (Fig. 1 D–E) and cleaved caspase-1 staining (Fig. 1 F–G) demonstrated that VSMC Nlrp3 GOF was sufficient to induce caspase-1 activation even in unligated arteries and further amplified ligation-induced caspase-1 activation in injured arteries. Together, these data establish a VSMC-intrinsic model of enhanced NLRP3–caspase-1 activity in the injured artery. This heightened inflammasome activation provides a mechanistic basis for downstream inflammatory signaling and vascular wall immune cell recruitment during remodeling. VSMC Nlrp3 gain-of-function exacerbates vascular inflammation after injury Vascular inflammation is a hallmark of intimal hyperplasia and is characterized by increased adhesion molecule expression and recruitment of inflammatory cells 26 . We therefore examined whether VSMC Nlrp3 GOF enhances inflammatory activation after injury. Consistent with our prior observations 18 , partial ligation markedly increased VCAM-1 expression in VSMC of the vessel wall, and this response was significantly greater in Nlrp3 SMKI mice, with the most prominent signal localized to the neointimal region (Fig. 2 A–B). In parallel, immunostaining for the pan-macrophage marker F4/80 (Fig. 2 C–D) revealed increased macrophage accumulation in ligated arteries, which was further amplified in Nlrp3 SMKI mice. Staining for M2-polarized macrophage marker CD206 (Fig. 2 E–F) also increased after injury and was elevated to a greater extent in ligated arteries from Nlrp3 SMKI mice. Together, these results support that VSMC-intrinsic NLRP3 hyperactivation potentiates injury-induced VCAM-1 upregulation and promotes macrophage accumulation within the remodeling vessel wall, thereby exacerbating vascular inflammation. Thus, VSMC NLRP3 hyperactivation amplifies endothelial/vascular inflammatory activation and creates a permissive environment for leukocyte adhesion and accumulation in the lesion. VSMC Nlrp3 gain-of-function enhances GSDMD upregulation and cell death after vascular injury Given the canonical linkage between NLRP3–caspase-1 activation and GSDMD-mediated pyroptotic signaling, we next assessed GSDMD and cell death in injured arteries. Consistent with our previous study 18 , partial ligation induced VSMC GSDMD upregulation in the vessel wall; notably, this increase was significantly greater in Nlrp3 SMKI mice (Fig. 3 A–B). Moreover, TUNEL staining showed that partial ligation-induced cell death was further increased by VSMC Nlrp3 GOF (Fig. 3 C–D). These findings are consistent with activation of the NLRP3–caspase-1–GSDMD axis in vivo. These findings link VSMC NLRP3 hyperactivation to activation of the caspase-1–GSDMD effector arm and increased cell death within the remodeling vessel wall. VSMC Nlrp3 gain-of-function promotes VSMC proliferation/migration and aggravates intimal hyperplasia Excessive VSMC proliferation and migration into the intima are central drivers of intimal hyperplasia during vascular remodeling 1 , 27 . Ki-67 is expressed in all active phases of the cell cycle and is widely used to quantify proliferating VSMCs in vascular lesions 28 . We observed that partial ligation increased the number of Ki-67-positive VSMCs in the vessel wall, and this proliferative response was significantly enhanced in Nlrp3 SMKI mice (Fig. 4 A–B). We next assessed VSMC migratory remodeling by examining MMP-2, a key mediator of extracellular matrix degradation and VSMC migration 29 . Strikingly, VSMC Nlrp3 GOF increased MMP-2 expression even in unligated arteries and further amplified ligation-induced MMP-2 upregulation in injured arteries (Fig. 4 C–D). We then evaluated structural remodeling endpoints. Sirius red staining demonstrated robust collagen deposition after ligation; however, total collagen accumulation was not further increased by VSMC Nlrp3 GOF (Fig. 5 A, 5 C). In contrast, H&E staining and morphometric analysis showed that ligation induced substantial intimal hyperplasia in Nlrp3 ctrl mice, and this response was significantly exacerbated in Nlrp3 SMKI mice, as reflected by increased intimal area and elevated intima-to-media ratio (Fig. 5 B, 5 D–E). Together, these data indicate that VSMC NLRP3 hyperactivation enhances proliferative/migratory remodeling and markedly worsens injury-induced intimal hyperplasia. VSMC Nlrp3 gain-of-function accelerates VSMC-to-foam cell transition VSMC-to-foam cell transition is a lipid-driven phenotypic switch involving metabolic reprogramming, and lineage-tracing/single-cell studies indicate that a substantial fraction of foam cells within mouse and human plaques can originate from VSMCs 8 , 9 . We therefore tested whether VSMC Nlrp3 GOF affects lipid accumulation within the injured vessel wall. Compared with controls, Nlrp3 SMKI arteries displayed significantly greater lipid deposition after injury, as demonstrated by Oil Red O staining (Fig. 6 A–B) and BODIPY staining (Fig. 6 C–D). Consistently, the lipid droplet coat protein PLIN2 was increased to a greater extent in Nlrp3 SMKI lesions (Fig. 6 E–F). These results demonstrate that VSMC NLRP3 hyperactivation promotes VSMC lipid loading and foam cell–like phenotypic transition in vivo. The enhanced lipid accumulation and PLIN2 induction suggest that NLRP3 hyperactivation promotes a metabolic shift in VSMCs toward lipid storage and foam cell–like phenotype. VSMC Nlrp3 gain-of-function impairs TFEB-mediated autophagy–lysosome signaling TFEB is a master transcriptional regulator of autophagy–lysosome pathways, coordinating lysosomal biogenesis, autophagosome formation, and cargo degradation 30 – 32 . Our prior study showed that TFEB signaling is suppressed in ligated carotid arteries 21 . Consistent with this, ligation reduced TFEB expression in VSMCs, and this decrease was significantly more pronounced in Nlrp3 SMKI arteries (Fig. 7 A–B), indicating that VSMC NLRP3 hyperactivation further suppresses TFEB during vascular remodeling. We next assessed lysosomal and autophagy markers. LAMP2A, a key receptor required for chaperone-mediated autophagy 33 , was increased by ligation in this dataset (in contrast to our previous observation 21 ). Notably, VSMC Nlrp3 gain-of-function counteracted this ligation-induced LAMP2A increase and reduced LAMP2A levels in VSMCs (Fig. 7 C–D). In addition, Nlrp3 SMKI arteries exhibited greater impairment of lysosome/autophagy markers, including reduced LAMP1 (Fig. 7 E–F) and decreased LC3 signal (Fig. 7 G–H) compared with Nlrp3 ctrl arteries after injury. Collectively, these data support that VSMC NLRP3 gain-of-function disrupts TFEB-associated autophagy–lysosome homeostasis during injury-induced vascular remodeling. Discussion In this study, we provide direct in vivo evidence that VSMC-intrinsic NLRP3 hyperactivation is sufficient to drive maladaptive vascular remodeling and markedly worsen intimal hyperplasia under hypercholesterolemic injury conditions. Using a VSMC-specific Nlrp3 gain-of-function knock-in model, we bypass the long-standing ambiguity inherent to systemic loss-of-function approaches and directly assign causality to VSMCs as the initiating and amplifying compartment in inflammasome-dependent lesion progression. Our data support a mechanistic cascade in which enhanced NLRP3–caspase-1 signaling in VSMCs augments vascular inflammation, engages the caspase-1–GSDMD effector arm, leading to increased cell death, promotes proliferative and migratory remodeling, and accelerates lipid loading and a VSMC-to–foam cell–like phenotypic transition, culminating in exacerbated neointimal growth. Recent studies have leveraged gain-of-function NLRP3 knock-in (KI) mice to model cryopyrin-associated periodic syndromes (CAPS) and to dissect how inflammasome hyperactivation drives tissue pathology. Seminal work by Hoffman and colleagues established KI strains carrying CAPS-linked mutations (e.g., A352V and L353P) and showed that these variants can trigger systemic inflammation and early mortality when expressed in myeloid lineages 19 . Since then, additional CAPS-relevant NLRP3 KI models—including D301N, R258W, and others—have been applied across diverse organ systems and cell types to reveal how cell-intrinsic NLRP3 hyperactivation shapes inflammation and disease phenotypes 34 , 35 . Although these models have been highly informative and increasingly adopted beyond classic autoinflammatory contexts, the potential contribution of cardiovascular-resident cells, particularly endothelial cells and vascular smooth muscle cells (VSMCs), to NLRP3-driven CAPS-like pathology and vascular remodeling remains poorly defined. Addressing this gap, we provide the first direct evidence that smooth muscle–restricted NLRP3 gain-of-function (L351P KI) is sufficient to activate the inflammasome program in vivo and to exacerbate injury-driven vascular remodeling. Notably, VSMC Nlrp3 gain-of-function increased inflammasome activation not only after partial carotid ligation under hypercholesterolemia, but also detectably in unligated arteries, as indicated by elevated FLICA labeling and cleaved caspase-1 staining. This suggests that VSMC inflammasome hyperactivation can establish a “primed” pro-inflammatory state that lowers the activation threshold of the vessel wall, thereby sensitizing arteries to subsequent hemodynamic or metabolic stress. Following injury, this primed state translated into a markedly amplified caspase-1 response, enhanced inflammatory activation and macrophage accumulation, and accelerated neointimal growth. Together, these findings support a model in which VSMC-intrinsic NLRP3 hyperactivation is an upstream driver, rather than a passive byproduct, of the inflammatory microenvironment that fuels pathological vascular remodeling. Future work should determine whether other CAPS-linked NLRP3 variants similarly reprogram VSMC function, define the downstream mediators coupling VSMC inflammasome activation to lesion progression, and test whether targeting VSMC NLRP3 signaling can mitigate vascular pathology in relevant disease settings. Consistent with this, VSMC NLRP3 hyperactivation significantly intensified vascular inflammatory activation and immune cell accumulation. VCAM-1 upregulation within the vessel wall was increased in Nlrp3 SMKI arteries, particularly within the neointimal region, accompanied by greater macrophage accumulation (F4/80 + ) and increased CD206 + macrophage staining after injury. Increased VCAM-1 provides a plausible molecular link between VSMC inflammasome activation and leukocyte adhesion and retention within lesions, thereby amplifying local inflammatory signaling. Elevated macrophage accumulation (F4/80+) indicates significant infiltration within the lesion, while increased CD206 + expression reflects a polarization toward a 'repair-associated' phenotype. These cells support lesion remodeling through growth factor production, matrix remodeling, and complex effects on lipid handling depending on context 36 , 37 . Together, these findings place VSMC NLRP3 activity upstream of a permissive inflammatory niche, poised to accelerate lesion development through both immune-dependent and immune-independent mechanisms. We further demonstrate that VSMC NLRP3 hyperactivation activates the caspase-1–GSDMD effector axis and is associated with increased cell death within the remodeling vessel wall. In Nlrp3 SMKI arteries, ligation elicited greater GSDMD upregulation accompanied by increased TUNEL positivity, consistent with enhanced inflammasome-linked cellular injury. Importantly, in the setting of intimal hyperplasia, cell death can be pro-remodeling rather than protective: pyroptosis-associated membrane permeabilization and release of inflammatory mediators and danger signals can amplify paracrine activation of neighboring vascular cells, promote chemokine/adhesion molecule expression, and trigger compensatory VSMC proliferation and migration. In parallel, inflammasome-derived IL-1 family cytokines directly support VSMC activation states that favor migratory and proliferative remodeling 38 – 40 . Notably, our recent work further indicates that GSDMD can promote platelet-derived growth factor-BB (PDGF-BB)–induced VSMC proliferation, migration, and inflammation independent of overt cell death 18 , highlighting a non-lytic remodeling function for this pathway. Together, these findings support a model in which NLRP3–caspase-1–GSDMD signaling accelerates neointimal growth through both inflammatory injury–driven feed-forward loops and cell-intrinsic, pro-remodeling effects on VSMC behavior. In line with this model, we observed that VSMC Nlrp3 gain-of-function robustly enhanced the proliferative and migratory programs that drive neointimal expansion. Nlrp3 SMKI arteries exhibited increased Ki-67–positive VSMCs after ligation and elevated MMP-2 expression, with a notable increase even in unligated arteries. These findings are consistent with the established paradigm that injury-induced phenotypic switching enables VSMCs to proliferate, degrade extracellular matrix via MMPs, and migrate into the intima to form neointimal lesions 41 . Importantly, these molecular and cellular changes translated into clear structural consequences: Nlrp3 SMKI mice developed significantly greater intimal hyperplasia, reflected by increased intimal area and a higher intima-to-media ratio—standard morphometric endpoints tightly linked to restenosis severity 42 , 43 . Although collagen deposition increased after injury, VSMC Nlrp3 gain-of-function did not further augment total collagen accumulation, suggesting that the predominant impact of VSMC inflammasome hyperactivation in this setting is cellular expansion and lesion architecture, rather than generalized fibrosis. This distinction is clinically relevant because VSMC accumulation and neointimal cellularity, more than collagen content per se, are major determinants of luminal narrowing and restenosis risk. Beyond lesion size, our findings extend VSMC inflammasome biology into the domain of lipid-driven phenotypic switching. We show that VSMC Nlrp3 gain-of-function significantly increased vascular lipid deposition (Oil Red O and BODIPY staining) and elevated PLIN2 expression in injured arteries, supporting accelerated VSMC lipid loading and foam cell–like transition. This observation is particularly important given accumulating evidence that VSMCs contribute substantially to foam cell populations in atherosclerotic plaques and can acquire macrophage-like transcriptional programs that complicate lesion biology and therapeutic targeting 8 , 9 . Functionally, VSMC-to-foam cell transition is not a benign lipid-storage state: it is associated with loss of canonical contractile identity, impaired matrix homeostasis, and reduced plaque-stabilizing functions of VSMCs, while promoting a pro-inflammatory, protease-rich, and stress-vulnerable phenotype that can increase necrotic core formation and lesion complexity 44 . In addition, lipid-laden VSMCs may be more prone to cell death and defective efferocytosis, thereby amplifying inflammatory signaling and contributing to the expansion of acellular/necrotic regions within lesions 45 . Consistent with this concept, an in vitro/in vivo study demonstrated that NLRP3 inflammasome activation promotes foam cell formation in human VSMCs and atherogenesis via HMGB1 46 . Thus, our data suggest that inflammasome hyperactivation within VSMCs is sufficient to bias VSMCs toward a lipid-storing, foam-like phenotype in vivo, providing a mechanistic link between inflammatory danger sensing and metabolic remodeling that can accelerate plaque progression and destabilizing features, beyond simply increasing lesion burden. Mechanistically, we observed that VSMC NLRP3 hyperactivation was accompanied by suppression of TFEB and broad impairment of autophagy–lysosome markers (LAMP1, LAMP2A, LC3) during vascular remodeling. These results suggest that lysosomal quality control is not simply a downstream bystander of injury, but a vulnerable node that is further destabilized by excessive VSMC inflammasome activity. Because lysosome–autophagy pathways are central to lipid droplet turnover and cellular stress resolution, their impairment provides a plausible explanation for the increased lipid accumulation and PLIN2 induction observed in Nlrp3 SMKI lesions. Moreover, lysosomal dysfunction can reinforce inflammation by promoting the accumulation of damaged organelles and endogenous danger signals, thereby creating a feed-forward loop that sustains, and can further amplify inflammasome signaling 47 . Importantly, TFEB suppression provides a unifying mechanism that extends beyond lipid handling. In our previous study, TFEB activation/overexpression restrained VSMC proliferation and migration, whereas TFEB silencing promoted these pro-remodeling behaviors 21 , 48 , 49 . Thus, NLRP3 hyperactivation–induced TFEB downregulation may contribute not only to VSMC foam cell–like transition, but also to the heightened proliferative and migratory remodeling that drives neointimal expansion. In addition, TFEB overexpression has been linked to enhanced antioxidant defenses and anti-inflammatory effects in endothelial cells 50 , offering a plausible pathway by which TFEB loss could further amplify vascular inflammation and injury responses in the lesion microenvironment. One unexpected observation was that LAMP2A increased in Nlrp3 ctrl arteries after ligation in this dataset, which differs from our prior report showing reduced LAMP2A in ligated arteries from wild type mice 21 . We interpret this injury-induced upregulation of LAMP2A as a potential compensatory response aimed at enhancing chaperone-mediated autophagy and restoring proteostasis under vascular stress. In contrast, LAMP2A was reduced in ligated arteries from Nlrp3 SMKI mice, indicating that VSMC Nlrp3 gain-of-function not only prevents the normal injury-induced LAMP2A induction, but shifts the response toward an overall loss of CMA capacity during remodeling. One possible contributor to the discrepancy across datasets is the Nlrp3 heterozygous background, which may alter baseline stress signaling and the magnitude/timing of compensatory programs. Alternatively, LAMP2A regulation may be stage-dependent, with an early adaptive induction in controls that becomes blunted, reversed, or insufficient when inflammasome activity is chronically heightened in VSMCs. Importantly, the broader marker pattern is internally consistent: TFEB was reduced, and lysosome/autophagy markers were further diminished in Nlrp3 SMKI arteries, supporting a net impairment of autophagy–lysosome homeostasis during remodeling. Collectively, these findings support an integrated model in which VSMC NLRP3 hyperactivation couples inflammatory/pyroptotic signaling with suppression of TFEB-linked stress-adaptive clearance pathways, thereby disabling compensatory proteostasis responses, promoting VSMC dysfunction, and accelerating lesion progression and foam cell–like phenotypic switching. From a translational perspective, these results elevate VSMC NLRP3 signaling as a therapeutic target to limit both restenosis-like neointimal hyperplasia and lipid-driven VSMC phenotypic switching. Systemic inflammasome or IL-1 pathway inhibition has shown promise in inflammatory cardiovascular contexts 51 , but broad immunosuppression can increase infection risk and may not optimally suppress vessel wall–localized remodeling programs. Our findings, therefore, motivate an alternative strategy: cell- or lesion-targeted inhibition of the NLRP3–caspase-1–GSDMD axis within the vascular wall, potentially using local delivery approaches (e.g., targeted nanoparticles) to reduce off-target effects while maximizing efficacy at the remodeling site. In addition, the tight coupling between inflammasome hyperactivation and foam-like lipid accumulation suggests that targeting VSMC inflammasome signaling may provide dual benefit—restraining neointimal growth while reducing lesion lipid burden and VSMC-derived foam cell formation. Complementing inflammasome-directed approaches, our data also suggest that restoring VSMC stress-adaptive programs downstream of NLRP3—particularly TFEB-mediated lysosome–autophagy capacity—may represent a second translational direction for vascular disease in CAPS-associated settings and cardiovascular diseases characterized by intimal hyperplasia. Given our prior evidence that TFEB activation suppresses VSMC proliferation and migration 21 , 48 , 49 , and the established role of lysosome–autophagy pathways in lipid clearance and inflammation control 50 , 52 , pharmacologic or gene-based activation of TFEB in VSMCs—potentially using the same lesion-targeted delivery platforms—could mitigate both structural remodeling and lipid-driven phenotypic switching. Thus, combined strategies that inhibit VSMC NLRP3 effector signaling and/or boost VSMC TFEB-driven protective clearance pathways may offer a rational, vessel wall–focused therapeutic framework to prevent restenosis and limit pathological VSMC plasticity. This study has limitations. First, our conclusions are based on a single injury paradigm (partial carotid ligation) under a hypercholesterolemic diet, and additional models, such as wire injury, will be needed to establish generalizability across clinically relevant forms of intimal hyperplasia. Second, although our data support a causal role for VSMC NLRP3 hyperactivation, the molecular intermediates linking VSMC inflammasome signaling to the suppression of TFEB and lysosome–autophagy programs remain to be defined. Third, future studies should determine whether pharmacologic inhibition of NLRP3/GSDMD (or VSMC-targeted inhibition) can rescue lesion phenotypes in Nlrp3 SMKI mice, and whether restoring TFEB-mediated lysosomal/autophagic capacity can blunt VSMC foam transition and lesion growth. In summary, our work establishes that VSMC-intrinsic NLRP3 hyperactivation is sufficient to drive VSMC dysfunction and accelerate intimal hyperplasia, while also promoting lipid accumulation and VSMC-to–foam cell–like phenotypic transition. Mechanistically, these pathological responses are accompanied by suppression of TFEB and impairment of TFEB-regulated lysosome–autophagy programs, identifying defective cellular clearance and stress adaptation as an additional axis downstream of inflammasome hyperactivation. Together, these findings resolve a key mechanistic gap by directly implicating VSMCs as a causative inflammasome-active compartment during vascular remodeling and suggest that the NLRP3–TFEB/lysosome pathway represents a translationally actionable target for preventing restenosis, limiting plaque progression, and restraining maladaptive VSMC phenotypic switching. Abbreviations α-SMA Alpha-smooth muscle actin CAPS Cryopyrin-associated periodic syndromes CVDs Cardiovascular diseases DAMPs Danger-associated molecular patterns DAPI 4',6-diamidino-2-phenylindole GSDMD Gasdermin D GOF Gain-of-function H&E staining Hematoxylin and eosin staining IL-1β Interleukin 1-beta LAMP Lysosome-associated membrane protein MMP Matrix metalloproteinase NLRP3 NOD-like receptor pyrin domain 3 TFEB Transcription factor EB VCAM 1 Vascular cell adhesion molecule 1 VSMCs Vascular smooth muscle cells Declarations Ethical approval and consent to participate Not applicable. Competing interests The authors declare no competing or conflicting interests. Funding This work was supported by grants from the National Institutes of Health (R01HL150007 and R01HL122937). Authors' contributions X.L. and Y.Z. designed the research and wrote the manuscript; Y-T.W. performed the experiments and contributed to writing the manuscript; Y-T.W., A.K.M., and R.Z. analyzed the data; W.G., B.K.M., G.L., and P-L.L. reviewed and edited the manuscript; and all authors have read and approved the final manuscript. Acknowledgment This work was also supported by the “New Faculty Program Award” and “Drug Discovery Institute Technique Expansion Track Award from University of Houston, and the American Heart Association (23IPA1046060, B.K.M.). Availability of data and material The authors declare that the data supporting the findings of this study are available within the paper. References Deglise S, Bechelli C, Allagnat F (2022) Vascular smooth muscle cells in intimal hyperplasia, an update. Front Physiol 13:1081881. 10.3389/fphys.2022.1081881 Cizek SM, Bedri S, Talusan P, Silva N, Lee H, Stone JR (2007) Risk factors for atherosclerosis and the development of preatherosclerotic intimal hyperplasia. Cardiovasc Pathol 16:344–350. 10.1016/j.carpath.2007.05.007 Nusca A, Viscusi MM, Piccirillo F, De Filippis A, Nenna A, Spadaccio C, Nappi F, Chello C, Mangiacapra F, Grigioni F et al (2022) Stent Neo-Atherosclerosis: Pathophysiology, Clinical Implications, Prevention, and Therapeutic Approaches. Life (Basel) 12. 10.3390/life12030393 Newby AC, Zaltsman AB (2000) Molecular mechanisms in intimal hyperplasia. J Pathol . ;190:300–309. doi: 10.1002/(SICI)1096-9896(200002)190:33.0.CO;2-I Cao G, Xuan X, Hu J, Zhang R, Jin H, Dong H (2022) How vascular smooth muscle cell phenotype switching contributes to vascular disease. Cell Commun Signal 20:180. 10.1186/s12964-022-00993-2 Tang HY, Chen AQ, Zhang H, Gao XF, Kong XQ, Zhang JJ (2022) Vascular Smooth Muscle Cells Phenotypic Switching in Cardiovascular Diseases. Cells 11. 10.3390/cells11244060 Sorokin V, Vickneson K, Kofidis T, Woo CC, Lin XY, Foo R, Shanahan CM (2020) Role of Vascular Smooth Muscle Cell Plasticity and Interactions in Vessel Wall Inflammation. Front Immunol 11:599415. 10.3389/fimmu.2020.599415 Fu Z, Yang S, Chang X, Liu P, Wang Y (2025) Vascular smooth muscle cell metabolic reprogramming and phenotypic remodeling in atherosclerosis. Cell Death Discov. 10.1038/s41420-025-02932-9 Jiao X, Guo D, Li W, Li S, Shao G, Shen T, Yu X (2025) Foam cells: tracing the diverse cellular origins and their linked signaling pathways. J Transl Med 23:1382. 10.1186/s12967-025-07402-5 Guo H, Callaway JB, Ting JP (2015) Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med 21:677–687. 10.1038/nm.3893 Abderrazak A, Syrovets T, Couchie D, El Hadri K, Friguet B, Simmet T, Rouis M (2015) NLRP3 inflammasome: from a danger signal sensor to a regulatory node of oxidative stress and inflammatory diseases. Redox Biol 4:296–307. 10.1016/j.redox.2015.01.008 Gonzalez-Moro A, Valencia I, Shamoon L, Sanchez-Ferrer CF, Peiro C, de la Cuesta F (2022) NLRP3 Inflammasome in Vascular Disease: A Recurrent Villain to Combat Pharmacologically. Antioxid (Basel) 11. 10.3390/antiox11020269 Zhou X, Wu Y, Ye L, Wang Y, Zhang K, Wang L, Huang Y, Wang L, Xian S, Zhang Y et al (2019) Aspirin alleviates endothelial gap junction dysfunction through inhibition of NLRP3 inflammasome activation in LPS-induced vascular injury. Acta Pharm Sin B 9:711–723. 10.1016/j.apsb.2019.02.008 Kesavardhana S, Malireddi RKS, Kanneganti TD (2020) Caspases in Cell Death, Inflammation, and Pyroptosis. Annu Rev Immunol 38:567–595. 10.1146/annurev-immunol-073119-095439 Huang Y, Xu W, Zhou R (2021) NLRP3 inflammasome activation and cell death. Cell Mol Immunol 18:2114–2127. 10.1038/s41423-021-00740-6 Lu N, Cheng W, Liu D, Liu G, Cui C, Feng C, Wang X (2022) NLRP3-Mediated Inflammation in Atherosclerosis and Associated Therapeutics. Front Cell Dev Biol 10:823387. 10.3389/fcell.2022.823387 Mo B, Ding Y, Ji Q (2025) NLRP3 inflammasome in cardiovascular diseases: an update. Front Immunol 16:1550226. 10.3389/fimmu.2025.1550226 Wang YT, Moura AK, Zuo R, Guan Y, Lee EA, Hu JZ, Roudbari K, Wang Z, Wang M, Li PL et al (2025) Contribution of NLRP3-GSDMD axis to PDGF-BB-induced vascular smooth muscle cell phenotypic transition. Am J Physiol Cell Physiol 329:C682–C698. 10.1152/ajpcell.00226.2025 Brydges SD, Mueller JL, McGeough MD, Pena CA, Misaghi A, Gandhi C, Putnam CD, Boyle DL, Firestein GS, Horner AA et al (2009) Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity. Immunity 30:875–887. 10.1016/j.immuni.2009.05.005 Nam D, Ni CW, Rezvan A, Suo J, Budzyn K, Llanos A, Harrison D, Giddens D, Jo H (2009) Partial carotid ligation is a model of acutely induced disturbed flow, leading to rapid endothelial dysfunction and atherosclerosis. Am J Physiol Heart Circ Physiol 297:H1535–1543. 10.1152/ajpheart.00510.2009 Wang YT, Li X, Chen J, McConnell BK, Chen L, Li PL, Chen Y, Zhang Y (2019) Activation of TFEB ameliorates dedifferentiation of arterial smooth muscle cells and neointima formation in mice with high-fat diet. Cell Death Dis 10:676. 10.1038/s41419-019-1931-4 Wang YT, Moura AK, Zuo R, Zhou W, Wang Z, Roudbari K, Hu JZ, Li PL, Zhang Y, Li X (2024) Coronary Microvascular Dysfunction Is Associated With Augmented Lysosomal Signaling in Hypercholesterolemic Mice. J Am Heart Assoc 13:e037460. 10.1161/JAHA.124.037460 Wang YT, Moura AK, Zuo R, Roudbari K, Hu JZ, Khan SA, Wang Z, Shentu Y, Wang M, Li PL et al (2025) Cardiovascular dysfunction and altered lysosomal signaling in a murine model of acid sphingomyelinase deficiency. J Mol Med (Berl) 103:599–617. 10.1007/s00109-025-02542-z Wang YT, Moura AK, Zuo R, Wang Z, Roudbari K, Hu JZ, Wang M, Li PL, Zhang Y, Li X (2025) Defective lipid droplet biogenesis exacerbates oleic acid-induced cellular homeostasis disruption and ferroptosis in mouse cardiac endothelial cells. Cell Death Discov 11:374. 10.1038/s41420-025-02669-5 Zuo R, Wang M, Wang YT, ShenTu Y, Moura AK, Zhou Y, Roudbari K, Hu JZ, Li PL, Hao J et al (2025) Ablation of Hepatic Asah1 Gene Disrupts Hepatic Lipid Homeostasis and Promotes Fibrotic Nonalcoholic Steatohepatitis in Mice. Am J Pathol 195:542–560. 10.1016/j.ajpath.2024.11.003 Baeza C, Ribagorda M, Maya-Lopez C, Fresno M, Sanchez-Diaz T, Pintor-Chocano A, Sanz AB, Carrasco S, Ortiz A, Sanchez-Nino MD (2024) NIK Is a Mediator of Inflammation and Intimal Hyperplasia in Endothelial Denudation-Induced Vascular Injury. Int J Mol Sci 25. 10.3390/ijms252111473 Luo H, Li Y, Song H, Zhao K, Li W, Hong H, Wang YT, Qi L, Zhang Y (2024) Role of EZH2-mediated epigenetic modification on vascular smooth muscle in cardiovascular diseases: A mini-review. Front Pharmacol 15:1416992. 10.3389/fphar.2024.1416992 Scholzen T, Gerdes J (2000) The Ki-67 protein: from the known and the unknown. J Cell Physiol 182:311–322. 10.1002/(SICI)1097-4652(200003)182:3%3C311::AID-JCP1%3E3.0.CO;2-9 Belo VA, Guimaraes DA, Castro MM (2015) Matrix Metalloproteinase 2 as a Potential Mediator of Vascular Smooth Muscle Cell Migration and Chronic Vascular Remodeling in Hypertension. J Vasc Res 52:221–231. 10.1159/000441621 Settembre C, Di Malta C, Polito VA, Garcia Arencibia M, Vetrini F, Erdin S, Erdin SU, Huynh T, Medina D, Colella P et al (2011) TFEB links autophagy to lysosomal biogenesis. Science 332:1429–1433. 10.1126/science.1204592 Wang Z, Li X, Moura AK, Hu JZ, Wang YT, Zhang Y (2025) Lysosome Functions in Atherosclerosis: A Potential Therapeutic Target. Cells 14. 10.3390/cells14030183 Zhang Y, Wang YT, Koka S, Zhang Y, Hussain T, Li X (2020) Simvastatin improves lysosome function via enhancing lysosome biogenesis in endothelial cells. Front Biosci (Landmark Ed) 25:283–298. 10.2741/4807 Hubert V, Weiss S, Rees AJ, Kain R (2022) Modulating Chaperone-Mediated Autophagy and Its Clinical Applications in Cancer. Cells 11. 10.3390/cells11162562 Bonar SL, Brydges SD, Mueller JL, McGeough MD, Pena C, Chen D, Grimston SK, Hickman-Brecks CL, Ravindran S, McAlinden A et al (2012) Constitutively activated NLRP3 inflammasome causes inflammation and abnormal skeletal development in mice. PLoS ONE 7:e35979. 10.1371/journal.pone.0035979 Meng G, Zhang F, Fuss I, Kitani A, Strober W (2009) A mutation in the Nlrp3 gene causing inflammasome hyperactivation potentiates Th17 cell-dominant immune responses. Immunity 30:860–874. 10.1016/j.immuni.2009.04.012 Wynn TA, Vannella KM (2016) Macrophages in Tissue Repair, Regeneration, and Fibrosis. Immunity 44:450–462. 10.1016/j.immuni.2016.02.015 Gandolfi S, Sanouj A, Chaput B, Coste A, Sallerin B, Varin A (2024) The role of adipose tissue-derived stromal cells, macrophages and bioscaffolds in cutaneous wound repair. Biol Direct 19:85. 10.1186/s13062-024-00534-6 Di C, Ji M, Li W, Liu X, Gurung R, Qin B, Ye S, Qi R (2025) Pyroptosis of Vascular Smooth Muscle Cells as a Potential New Target for Preventing Vascular Diseases. Cardiovasc Drugs Ther 39:1427–1438. 10.1007/s10557-024-07578-w Ji N, Qi Z, Wang Y, Yang X, Yan Z, Li M, Ge Q, Zhang J (2021) Pyroptosis: A New Regulating Mechanism in Cardiovascular Disease. J Inflamm Res 14:2647–2666. 10.2147/JIR.S308177 Zhou QY, Liu W, Gong SX, Tian Y, Ma XF, Wang AP (2024) Pulmonary artery smooth muscle cell pyroptosis promotes the proliferation of PASMCs by paracrine IL–1beta and IL–18 in monocrotaline–induced pulmonary arterial hypertensive rats. Exp Ther Med 28:394. 10.3892/etm.2024.12683 Chakraborty R, Chatterjee P, Dave JM, Ostriker AC, Greif DM, Rzucidlo EM, Martin KA (2021) Targeting smooth muscle cell phenotypic switching in vascular disease. JVS Vasc Sci 2:79–94. 10.1016/j.jvssci.2021.04.001 Pereira VL Jr., Dobre M, Dos Santos SG, Fuzatti JS, Oliveira CR, Campos LA, Brateanu A, Baltatu OC (2017) Association between Carotid Intima Media Thickness and Heart Rate Variability in Adults at Increased Cardiovascular Risk. Front Physiol 8:248. 10.3389/fphys.2017.00248 Tao M, Mauro CR, Yu P, Favreau JT, Nguyen B, Gaudette GR, Ozaki CK (2013) A simplified murine intimal hyperplasia model founded on a focal carotid stenosis. Am J Pathol 182:277–287. 10.1016/j.ajpath.2012.10.002 Yu Y, Cai Y, Yang F, Yang Y, Cui Z, Shi D, Bai R (2024) Vascular smooth muscle cell phenotypic switching in atherosclerosis. Heliyon 10:e37727. 10.1016/j.heliyon.2024.e37727 Beck-Joseph J, Tabrizian M, Lehoux S (2021) Molecular Interactions Between Vascular Smooth Muscle Cells and Macrophages in Atherosclerosis. Front Cardiovasc Med 8:737934. 10.3389/fcvm.2021.737934 Wang R, Wu W, Li W, Huang S, Li Z, Liu R, Shan Z, Zhang C, Li W, Wang S (2018) Activation of NLRP3 Inflammasome Promotes Foam Cell Formation in Vascular Smooth Muscle Cells and Atherogenesis Via HMGB1. J Am Heart Assoc 7:e008596. 10.1161/JAHA.118.008596 Weber K, Schilling JD (2014) Lysosomes integrate metabolic-inflammatory cross-talk in primary macrophage inflammasome activation. J Biol Chem 289:9158–9171. 10.1074/jbc.M113.531202 Li X, Zhao W, Wang Z, Moura AK, Roudbari K, Zuo R, Hu JZ, Wang YT, Li PL, Zhang Y (2025) Acid Sphingomyelinase Regulates AdipoRon-Induced Differentiation of Arterial Smooth Muscle Cells via TFEB Activation. Int J Mol Sci 26. 10.3390/ijms26052147 Wang YT, Chen J, Li X, Umetani M, Chen Y, Li PL, Zhang Y (2019) Contribution of transcription factor EB to adipoRon-induced inhibition of arterial smooth muscle cell proliferation and migration. Am J Physiol Cell Physiol 317:C1034–C1047. 10.1152/ajpcell.00294.2019 Lu H, Fan Y, Qiao C, Liang W, Hu W, Zhu T, Zhang J, Chen YE (2017) TFEB inhibits endothelial cell inflammation and reduces atherosclerosis. Sci Signal 10. 10.1126/scisignal.aah4214 Ridker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD et al (2017) Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med 377:1119–1131. 10.1056/NEJMoa1707914 Li M, Wang Z, Wang P, Li H, Yang L (2021) TFEB: A Emerging Regulator in Lipid Homeostasis for Atherosclerosis. Front Physiol 12:639920. 10.3389/fphys.2021.639920 Supplementary Files Keymessages.docx Cite Share Download PDF Status: Under Revision Version 1 posted Editorial decision: Major Revisions Needed 13 Mar, 2026 Reviewers agreed at journal 10 Feb, 2026 Reviewers invited by journal 09 Feb, 2026 Editor assigned by journal 30 Jan, 2026 First submitted to journal 29 Jan, 2026 You are reading this latest preprint version Research Square lets you share your work early, gain feedback from the community, and start making changes to your manuscript prior to peer review in a journal. As a division of Research Square Company, we’re committed to making research communication faster, fairer, and more useful. We do this by developing innovative software and high quality services for the global research community. Our growing team is made up of researchers and industry professionals working together to solve the most critical problems facing scientific publishing. Also discoverable on Platform About Our Team In Review Editorial Policies Advisory Board Help Center Resources Author Services Accessibility API Access RSS feed Manage Cookie Preferences © Research Square 2026 | ISSN 2693-5015 (online) Privacy Policy Terms of Service Do Not Sell My Personal Information {"props":{"pageProps":{"initialData":{"identity":"rs-8734377","acceptedTermsAndConditions":true,"allowDirectSubmit":false,"archivedVersions":[],"articleType":"Research Article","associatedPublications":[],"authors":[{"id":588372830,"identity":"3c03b65c-d55a-4b4c-b6fb-29d14d3046b7","order_by":0,"name":"Yun-Ting Wang","email":"","orcid":"","institution":"University of Houston","correspondingAuthor":false,"prefix":"","firstName":"Yun-Ting","middleName":"","lastName":"Wang","suffix":""},{"id":588372831,"identity":"2b678af0-24aa-4af0-8291-665352dad407","order_by":1,"name":"Alexandra K Moura","email":"","orcid":"","institution":"University of Houston","correspondingAuthor":false,"prefix":"","firstName":"Alexandra","middleName":"K","lastName":"Moura","suffix":""},{"id":588372832,"identity":"73516d2c-b2d2-47e0-abf3-8712c22775e4","order_by":2,"name":"Rui Zuo","email":"","orcid":"","institution":"University of Houston","correspondingAuthor":false,"prefix":"","firstName":"Rui","middleName":"","lastName":"Zuo","suffix":""},{"id":588372833,"identity":"2ec02a1c-d85f-4018-b1f8-d8cc13de9ab6","order_by":3,"name":"Wei Gao","email":"","orcid":"","institution":"University of Houston","correspondingAuthor":false,"prefix":"","firstName":"Wei","middleName":"","lastName":"Gao","suffix":""},{"id":588372834,"identity":"bb50adf9-825c-40e5-b40d-7a4ca62eae68","order_by":4,"name":"Bradley K McConnell","email":"","orcid":"","institution":"University of Houston","correspondingAuthor":false,"prefix":"","firstName":"Bradley","middleName":"K","lastName":"McConnell","suffix":""},{"id":588372835,"identity":"938adb6e-fdfd-4e3e-9a7f-a8ad072b70c9","order_by":5,"name":"Guangbi Li","email":"","orcid":"","institution":"Virginia Commonwealth University","correspondingAuthor":false,"prefix":"","firstName":"Guangbi","middleName":"","lastName":"Li","suffix":""},{"id":588372836,"identity":"d66f0136-c0cd-4fe3-9e81-362e37ff5984","order_by":6,"name":"Pin-Lan Li","email":"","orcid":"","institution":"Virginia Commonwealth University","correspondingAuthor":false,"prefix":"","firstName":"Pin-Lan","middleName":"","lastName":"Li","suffix":""},{"id":588372837,"identity":"e525ea7c-774d-41df-ac08-77bf4347bcfc","order_by":7,"name":"Xiang Li","email":"","orcid":"","institution":"University of Houston","correspondingAuthor":false,"prefix":"","firstName":"Xiang","middleName":"","lastName":"Li","suffix":""},{"id":588372838,"identity":"d7b069c7-45f7-4262-bfe3-bd7671ed468c","order_by":8,"name":"Yang Zhang","email":"data:image/png;base64,iVBORw0KGgoAAAANSUhEUgAAAZAAAAAyAQMAAABI0h/eAAAABlBMVEX///8AAABVwtN+AAAACXBIWXMAAA7EAAAOxAGVKw4bAAABAElEQVRIiWNgGAWjYFACHiCukJDjh3JlICJshLScsTCWbADSB8BcYrQwtlUkbjhArBaD82cPfi5gk0jcfPzwsccf99jxMEjkHmD4UHYYt5YD55KlZ/BIGG87k5ZucOBZMlBLXgLjjHN4tBzsMZDmkZCQ3XaDx0ziwAFmoJYcA2beNjxaDvMY/+YxkGDcPIP/G1BLPUTLX3xajvGYSfMkSChukOBhA2o5DNHCiEeL5BkeM2ueAxLGEmfSzCTOHDjOw8bzBujac+k4tfCdP2N8m/dfnRx/++FnEhUHquX42XMMH/wos8apReEAuggoRjAEkYF8Az7ZUTAKRsEoGAUgAADPClDtv98IzgAAAABJRU5ErkJggg==","orcid":"https://orcid.org/0000-0002-8338-3013","institution":"University of Houston","correspondingAuthor":true,"prefix":"","firstName":"Yang","middleName":"","lastName":"Zhang","suffix":""}],"badges":[],"createdAt":"2026-01-29 18:14:25","currentVersionCode":1,"declarations":"","doi":"10.21203/rs.3.rs-8734377/v1","doiUrl":"https://doi.org/10.21203/rs.3.rs-8734377/v1","draftVersion":[],"editorialEvents":[],"editorialNote":"","failedWorkflow":false,"files":[{"id":102451673,"identity":"54845071-ce50-4ccd-ad7b-ab646a350da3","added_by":"auto","created_at":"2026-02-11 19:07:06","extension":"jpg","order_by":1,"title":"Figure 1","display":"","copyAsset":false,"role":"figure","size":16530885,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eVSMC-specific knock-in of the \u003c/strong\u003e\u003cem\u003e\u003cstrong\u003eNlrp3\u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003e L351P mutant gene triggers NLRP3 inflammasome activation.\u0026nbsp; A. \u003c/strong\u003eGenotyping of VSMC-specific \u003cem\u003eNlrp3\u003c/em\u003e L351P mutant gene knock-in (KI) mouse strain (\u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003eL351P/+\u003c/sup\u003e/Myh11\u003csup\u003eCre\u003c/sup\u003e, \u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003eSMKI\u003c/sup\u003e) and littermate control (\u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003eL351P/+\u003c/sup\u003e/WT, \u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003ectrl\u003c/sup\u003e). \u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003eSMKI\u003c/sup\u003e and\u003cem\u003e Nlrp3\u003c/em\u003e \u003csup\u003ectrl\u003c/sup\u003e mice were subjected to partial carotid ligation surgery in left carotid arteries (ligated), while the right carotid arteries were used as unligated controls. All mice were fed a high-fat/high-cholesterol Paigen diet as described in Methods. (\u003cstrong\u003eB-C\u003c/strong\u003e) Representative immunofluorescence images show the expression of NLRP3 (red), α-SMA (green), and DAPI (blue), and quantification of colocalization (Pearson correlation coefficient, PCC) between NLRP3 and α-SMA within the vessel wall region (intima + media). (\u003cstrong\u003eD-E\u003c/strong\u003e) Representative images and quantification of caspase-1 activation using the FLICA active caspase-1 probe (green) within the vessel wall region (intima + media). Nuclei were counterstained with Hoechst (blue).\u0026nbsp; (\u003cstrong\u003eF–G\u003c/strong\u003e) Representative images showing cleaved caspase-1 (red), α-SMA (green), and DAPI (blue), and quantification of PCC between cleaved caspase-1 and α-SMA within the vessel wall region (intima + media). Scale bar=50 µm. Data are shown as fold-changes compared to the mean of control group (\u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003ectrl\u003c/sup\u003e unligated), which was set to 1.\u0026nbsp; The Kruskal-Wallis’s test was used, followed by Dunn's multiple comparisons test. *P\u0026lt; 0.05 (n=7-8 mice).\u003c/p\u003e","description":"","filename":"Figure1.jpg","url":"https://assets-eu.researchsquare.com/files/rs-8734377/v1/710fdaa06029d68816481536.jpg"},{"id":102451670,"identity":"cd7efd85-8e83-4170-8fec-f0b275ff3f48","added_by":"auto","created_at":"2026-02-11 19:07:06","extension":"jpg","order_by":2,"title":"Figure 2","display":"","copyAsset":false,"role":"figure","size":12775881,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eVSMC-specific \u003c/strong\u003e\u003cem\u003e\u003cstrong\u003eNlrp3\u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003e KI increases vascular injury-induced VCAM-1 expression and macrophage infiltration. \u003c/strong\u003e\u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003eSMKI\u003c/sup\u003e and\u003cem\u003e Nlrp3\u003c/em\u003e \u003csup\u003ectrl\u003c/sup\u003e mice were treated as in Figure.1. (\u003cstrong\u003eA-B\u003c/strong\u003e) Representative immunofluorescence images showing VCAM-1 (red), α-SMA (green), and DAPI (blue), and quantification of PCC between VCAM-1 and α-SMA within the vessel wall region (intima + media) (normalized to \u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003ectrl\u003c/sup\u003e unligated). (\u003cstrong\u003eC-D\u003c/strong\u003e) Representative images showing F4/80 (red), α-SMA (green), and DAPI (blue), and quantification of F4/80\u003csup\u003e+\u003c/sup\u003e macrophages within the vessel wall region (intima + media). (\u003cstrong\u003eE–F\u003c/strong\u003e) Representative images showing CD206 (red), α-SMA (green), and DAPI (blue), and quantification of CD206\u003csup\u003e+\u003c/sup\u003e macrophages within the vessel wall region (intima + media). Scale bar=50 µm. The Kruskal-Wallis’s test was used, followed by Dunn's multiple comparisons test. *P\u0026lt; 0.05 (n=7-8). \u0026nbsp;\u0026nbsp;\u003cstrong\u003e\u0026nbsp;\u0026nbsp;\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e","description":"","filename":"Figure2.jpg","url":"https://assets-eu.researchsquare.com/files/rs-8734377/v1/331ad790889c6c4e0eea04a0.jpg"},{"id":102451669,"identity":"0324d184-aaff-4b97-9011-ba8f0df3b8d7","added_by":"auto","created_at":"2026-02-11 19:07:06","extension":"jpg","order_by":3,"title":"Figure 3","display":"","copyAsset":false,"role":"figure","size":9039277,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eVSMC-specific \u003c/strong\u003e\u003cem\u003e\u003cstrong\u003eNlrp3\u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003e KI enhances GSDMD upregulation and cell death after vascular injury.\u003c/strong\u003e\u003cem\u003e Nlrp3\u003c/em\u003e \u003csup\u003eSMKI\u003c/sup\u003e and\u003cem\u003e Nlrp3\u003c/em\u003e \u003csup\u003ectrl\u003c/sup\u003e mice were treated as in Figure.1. (\u003cstrong\u003eA-B\u003c/strong\u003e) Representative immunofluorescence images showing GSDMD (red) and α-SMA (green), and quantification of PCC between GSDMD and α-SMA within the vessel wall region (intima + media) (normalized to \u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003ectrl\u003c/sup\u003e unligated). (\u003cstrong\u003eC-D\u003c/strong\u003e) Representative TUNEL images and quantification of TUNEL^+ cells within the vessel wall region (intima + media). Elastin autofluorescence is shown. Scale bar=50 µm. The Kruskal-Wallis’s test was used, followed by Dunn's multiple comparisons test. *P\u0026lt; 0.05 (n=7-8).\u0026nbsp; \u003cstrong\u003e\u0026nbsp;\u0026nbsp;\u0026nbsp;\u003c/strong\u003e\u003c/p\u003e","description":"","filename":"Figure3.jpg","url":"https://assets-eu.researchsquare.com/files/rs-8734377/v1/362eb3f030c35cc2f94d5a45.jpg"},{"id":102745563,"identity":"e19ae15d-cb76-4eb8-a366-2f9140f0c5ab","added_by":"auto","created_at":"2026-02-16 08:51:47","extension":"jpg","order_by":4,"title":"Figure 4","display":"","copyAsset":false,"role":"figure","size":15143405,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eVSMC-specific \u003c/strong\u003e\u003cem\u003e\u003cstrong\u003eNlrp3\u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003e KI promotes VSMC proliferation and migration-associated signaling after vascular injury.\u003c/strong\u003e\u003cem\u003e Nlrp3\u003c/em\u003e \u003csup\u003eSMKI\u003c/sup\u003e and\u003cem\u003e Nlrp3\u003c/em\u003e \u003csup\u003ectrl\u003c/sup\u003e mice were treated as in Figure.1. \u003cstrong\u003e(A-B)\u003c/strong\u003e Representative immunofluorescence images showing Ki67 (red), α-SMA (green), and DAPI (blue), and quantification of Ki67\u003csup\u003e+\u003c/sup\u003e cells within the vessel wall region (intima + media). \u003cstrong\u003e(C-D) \u003c/strong\u003eRepresentative images showing MMP-2 (red), α-SMA (green), and DAPI (blue), and quantification of PCC between MMP-2 and α-SMA within the vessel wall region (intima + media). Scale bar=50 µm. Data are shown as fold-changes compared to the mean of control group (\u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003ectrl\u003c/sup\u003e unligated), which was set to 1.\u0026nbsp; The Kruskal-Wallis’s test was used, followed by Dunn's multiple comparisons test. *P\u0026lt; 0.05 (n=7-8 mice).\u003c/p\u003e","description":"","filename":"Figure4.jpg","url":"https://assets-eu.researchsquare.com/files/rs-8734377/v1/e8a57d634a979621221594af.jpg"},{"id":102451672,"identity":"8701d449-c548-42cf-8119-87404a164a53","added_by":"auto","created_at":"2026-02-11 19:07:06","extension":"jpg","order_by":5,"title":"Figure 5","display":"","copyAsset":false,"role":"figure","size":8622901,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eVSMC-specific \u003c/strong\u003e\u003cem\u003e\u003cstrong\u003eNlrp3\u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003e KI exacerbates vascular injury–induced intimal hyperplasia. \u003c/strong\u003e\u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003eSMKI\u003c/sup\u003e and\u003cem\u003e Nlrp3\u003c/em\u003e \u003csup\u003ectrl\u003c/sup\u003e mice were treated as in Figure.1. (\u003cstrong\u003eA\u003c/strong\u003e) Representative Sirius Red/Fast Green staining showing collagen deposition. (\u003cstrong\u003eB\u003c/strong\u003e) Representative H\u0026amp;E staining showing intimal hyperplasia in carotid arteries; the intima is indicated by arrows. (\u003cstrong\u003eC\u003c/strong\u003e) Quantification of Sirius Red–positive area. (\u003cstrong\u003eD–E\u003c/strong\u003e) Quantification of intimal area and intima-to-media ratio. Scale bar= 50 μm. Data in panel D and E are shown as fold-changes compared to the mean of control group (\u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003e+/+\u003c/sup\u003e unligated), which was set to 1. The Kruskal-Wallis’s test was used, followed by Dunn's multiple comparisons test. *P\u0026lt; 0.05 (n = 7-8).\u0026nbsp;\u003c/p\u003e","description":"","filename":"Figure5.jpg","url":"https://assets-eu.researchsquare.com/files/rs-8734377/v1/8fc9583746a9162a1ef5c692.jpg"},{"id":102451674,"identity":"01372178-2b9c-422e-aa89-b2c20567921a","added_by":"auto","created_at":"2026-02-11 19:07:07","extension":"jpg","order_by":6,"title":"Figure 6","display":"","copyAsset":false,"role":"figure","size":13707193,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eVSMC-specific \u003c/strong\u003e\u003cem\u003e\u003cstrong\u003eNlrp3\u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003e KI exacerbates vascular injury-induced VSMC-to-foam cell-like transition. \u003c/strong\u003e\u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003eSMKI\u003c/sup\u003e and\u003cem\u003e Nlrp3\u003c/em\u003e \u003csup\u003ectrl\u003c/sup\u003e mice were treated as in Figure.1. (\u003cstrong\u003eA-B\u003c/strong\u003e) Representative Oil Red O staining and quantification of Oil Red O–positive area. (\u003cstrong\u003eC-D\u003c/strong\u003e) Representative immunofluorescence images showing BODIPY lipid staining (green), α-SMA (red), and DAPI (blue), and quantification of PCC between BODIPY and α-SMA within the vessel wall region (intima + media). (\u003cstrong\u003eE-F\u003c/strong\u003e) Representative images showing PLIN2 (red), α-SMA (green), and DAPI (blue), and quantification of PCC between PLIN2 and α-SMA within the vessel wall region (intima + media). Scale bar=50 µm. Data are shown as fold-changes compared to the mean of control group (\u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003ectrl\u003c/sup\u003e unligated), which was set to 1.\u0026nbsp; The Kruskal-Wallis’s test was used, followed by Dunn's multiple comparisons test. *P\u0026lt; 0.05 (n=7-8 mice). \u0026nbsp;\u003c/p\u003e","description":"","filename":"Figure6.jpg","url":"https://assets-eu.researchsquare.com/files/rs-8734377/v1/f22515f55b7c1125979c13dc.jpg"},{"id":102451675,"identity":"c2a15e08-4588-4864-9224-7659e4408de8","added_by":"auto","created_at":"2026-02-11 19:07:07","extension":"jpg","order_by":7,"title":"Figure 7","display":"","copyAsset":false,"role":"figure","size":19674166,"visible":true,"origin":"","legend":"\u003cp\u003e\u003cstrong\u003eVSMC-specific \u003c/strong\u003e\u003cem\u003e\u003cstrong\u003eNlrp3\u003c/strong\u003e\u003c/em\u003e\u003cstrong\u003e KI impairs TFEB-associated lysosome–autophagy signaling after vascular injury. \u003c/strong\u003e\u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003eSMKI\u003c/sup\u003e and\u003cem\u003e Nlrp3\u003c/em\u003e \u003csup\u003ectrl\u003c/sup\u003e mice were treated as in Figure.1. (\u003cstrong\u003eA–B\u003c/strong\u003e) Representative immunofluorescence images showing TFEB (red), α-SMA (green), and DAPI (blue), and quantification of PCC between TFEB and α-SMA within the vessel wall region (intima + media). (\u003cstrong\u003eC–D\u003c/strong\u003e) Representative images showing LAMP-2A (red), α-SMA (green), and DAPI (blue), and quantification of PCC between LAMP-2A and α-SMA within the vessel wall region (intima + media). (\u003cstrong\u003eE–F\u003c/strong\u003e) Representative images showing LAMP-1 (red), α-SMA (green), and DAPI (blue), and quantification of PCC between LAMP-1 and α-SMA within the vessel wall region (intima + media). (\u003cstrong\u003eG–H\u003c/strong\u003e) Representative images showing LC3 (red), α-SMA (green), and DAPI (blue), and quantification of PCC between LC3 and α-SMA within the vessel wall region (intima + media). Scale bar=50 µm. Data are shown as fold-changes compared to the mean of control group (\u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003ectrl\u003c/sup\u003e unligated), which was set to 1.\u0026nbsp; The Kruskal-Wallis’s test was used, followed by Dunn's multiple comparisons test. *P\u0026lt; 0.05 (n=7-8 mice).\u003c/p\u003e","description":"","filename":"Figure7.jpg","url":"https://assets-eu.researchsquare.com/files/rs-8734377/v1/bdb0907ecf3f1cc44d759681.jpg"},{"id":102750277,"identity":"a22c9b52-5e32-416d-be7f-628c9f8bdff8","added_by":"auto","created_at":"2026-02-16 09:18:49","extension":"pdf","order_by":0,"title":"","display":"","copyAsset":false,"role":"manuscript-pdf","size":96781403,"visible":true,"origin":"","legend":"","description":"","filename":"manuscript.pdf","url":"https://assets-eu.researchsquare.com/files/rs-8734377/v1/1f4b7f87-7693-4a51-8237-3992695c9fac.pdf"},{"id":102451668,"identity":"17653293-cf0e-45f2-8547-7990f2c8615f","added_by":"auto","created_at":"2026-02-11 19:07:06","extension":"docx","order_by":1,"title":"","display":"","copyAsset":false,"role":"supplement","size":13578,"visible":true,"origin":"","legend":"","description":"","filename":"Keymessages.docx","url":"https://assets-eu.researchsquare.com/files/rs-8734377/v1/b4c06f73bbd0323d013df1bd.docx"}],"financialInterests":"","formattedTitle":"Vascular Smooth Muscle–Specific NLRP3 Hyperactivation Drives Arterial Intimal Hyperplasia in Mice","fulltext":[{"header":"Introduction","content":"\u003cp\u003eIntimal hyperplasia is a major pathological driver of restenosis after vascular interventions and contributes to lumen narrowing during atherosclerotic disease progression \u003csup\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e,\u003cspan citationid=\"CR2\" class=\"CitationRef\"\u003e2\u003c/span\u003e\u003c/sup\u003e. Despite improvements in stent design and adjunct pharmacotherapy, neointimal lesion formation remains a common and clinically significant obstacle \u003csup\u003e\u003cspan citationid=\"CR3\" class=\"CitationRef\"\u003e3\u003c/span\u003e\u003c/sup\u003e. At the tissue level, intimal hyperplasia reflects a coordinated response to vascular injury and disturbed flow, involving inflammatory activation of the vessel wall, recruitment of leukocytes, and remodeling of extracellular matrix that collectively promote neointimal growth \u003csup\u003e\u003cspan citationid=\"CR4\" class=\"CitationRef\"\u003e4\u003c/span\u003e\u003c/sup\u003e. Defining the cell-intrinsic mechanisms that amplify this maladaptive remodeling program is essential for developing more precise, vessel wall\u0026ndash;directed therapies.\u003c/p\u003e \u003cp\u003eVascular smooth muscle cells (VSMCs) are central effectors of intimal hyperplasia. Following injury, VSMCs undergo phenotypic switching from a contractile to a synthetic state, characterized by enhanced proliferation, migration into the intima, and secretion of remodeling factors, such as matrix metalloproteinases \u003csup\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e,\u003cspan citationid=\"CR5\" class=\"CitationRef\"\u003e5\u003c/span\u003e,\u003cspan citationid=\"CR6\" class=\"CitationRef\"\u003e6\u003c/span\u003e\u003c/sup\u003e. This plasticity is strongly influenced by inflammatory cues and cell stress, which can create feed-forward loops that perpetuate VSMC dysfunction and accelerate lesion progression \u003csup\u003e\u003cspan citationid=\"CR7\" class=\"CitationRef\"\u003e7\u003c/span\u003e\u003c/sup\u003e. Beyond classical neointimal expansion, growing evidence from lineage-tracing and single-cell studies indicates that VSMCs can adopt macrophage-like gene programs and contribute substantially to foam cell populations in mouse and human atherosclerotic plaques \u003csup\u003e\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e,\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u003c/sup\u003e. Thus, VSMC maladaptation encompasses not only proliferative/migratory remodeling but also lipid-driven phenotypic transitions that can worsen lesion burden and complexity.\u003c/p\u003e \u003cp\u003eInflammasomes are innate immune signaling platforms that couple cellular stress sensing to inflammatory effector outputs \u003csup\u003e\u003cspan citationid=\"CR10\" class=\"CitationRef\"\u003e10\u003c/span\u003e\u003c/sup\u003e. Among them, the NLRP3 inflammasome is activated by diverse vascular disease\u0026ndash;relevant stimuli, including oxidative stress, and lipid-associated danger signals \u003csup\u003e\u003cspan additionalcitationids=\"CR12\" citationid=\"CR11\" class=\"CitationRef\"\u003e11\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR13\" class=\"CitationRef\"\u003e13\u003c/span\u003e\u003c/sup\u003e. Upon activation, NLRP3 promotes caspase-1 activation, which drives the maturation of IL-1β/IL-18 and the cleavage of GSDMD, leading to pore formation, the release of inflammatory mediators, and pyroptosis-associated cell injury \u003csup\u003e\u003cspan citationid=\"CR14\" class=\"CitationRef\"\u003e14\u003c/span\u003e,\u003cspan citationid=\"CR15\" class=\"CitationRef\"\u003e15\u003c/span\u003e\u003c/sup\u003e. Consistent with these functions, NLRP3 pathway activation has been implicated in atherosclerosis and post-injury vascular remodeling \u003csup\u003e\u003cspan additionalcitationids=\"CR17\" citationid=\"CR16\" class=\"CitationRef\"\u003e16\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e\u003c/sup\u003e. However, the vascular wall contains multiple potential cellular sources of NLRP3 activity, including infiltrating immune cells, endothelial cells, and VSMCs, making it difficult to determine whether NLRP3 signaling in VSMCs is sufficient to initiate and sustain the remodeling cascade culminating in intimal hyperplasia and lipid-laden VSMC phenotypes.\u003c/p\u003e \u003cp\u003eOur recent work showed that carotid partial ligation injury under hypercholesterolemic conditions activates the NLRP3 inflammasome in VSMCs and that global \u003cem\u003eNlrp3\u003c/em\u003e deficiency attenuates injury-induced inflammasome activation and intimal hyperplasia \u003csup\u003e\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e\u003c/sup\u003e. While these findings support a causal role for NLRP3 signaling in vascular remodeling, global loss-of-function approaches cannot distinguish the relative contributions of hematopoietic versus vessel wall\u0026ndash;resident compartments, nor can they directly establish the sufficiency of VSMC-intrinsic NLRP3 activation in driving VSMC dysfunction in vivo \u003csup\u003e\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e\u003c/sup\u003e. This knowledge gap is highly relevant to translational strategy: if VSMC-intrinsic NLRP3 hyperactivation is sufficient to amplify inflammation, pyroptosis-associated injury, and proliferative/migratory remodeling, then targeting NLRP3 signaling specifically within VSMCs could represent a focused therapeutic avenue to limit neointimal growth while reducing systemic immune perturbation.\u003c/p\u003e \u003cp\u003eHere, we directly test the VSMC-intrinsic contribution of NLRP3 by generating a VSMC-specific \u003cem\u003eNlrp3\u003c/em\u003e gain-of-function model. We crossed \u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003eL351PneoR\u003c/sup\u003e mice with Myh11-Cre to create \u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003eL351P/+/Myh11\u0026minus;Cre\u003c/sup\u003e mice (\u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003eSMKI\u003c/sup\u003e) and littermate controls, leveraging a gain-of-function NLRP3 substitution analogous to a human cryopyrin-associated periodic syndromes (CAPS)-associated mutation that enhances inflammasome activation \u003csup\u003e\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e\u003c/sup\u003e. Using carotid partial ligation combined with a Paigen diet to induce hypercholesterolemia-associated remodeling \u003csup\u003e\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e\u003c/sup\u003e, we assessed inflammasome activation, vascular inflammation, GSDMD-linked cell injury, VSMC proliferation and migration, neointimal lesion growth, and lipid accumulation associated with VSMC-to\u0026ndash;foam cell\u0026ndash;like transition in vivo. This approach provides direct mechanistic evidence for how VSMC-intrinsic NLRP3 hyperactivation programs maladaptive vascular remodeling and identifies VSMC NLRP3 signaling as a translationally actionable target to treat intimal hyperplasia and VSMC-driven foam cell transition.\u003c/p\u003e"},{"header":"Materials and Methods","content":"\u003cdiv id=\"Sec3\" class=\"Section2\"\u003e \u003ch2\u003eAntibodies and reagents\u003c/h2\u003e \u003cp\u003ePrimary antibodies: NLRP3 (Biotechne MAB7578), cleaved-caspase1 (Affinity AF4005), FITC-α-SMA (Sigma F3777), Cy3-αSMA (Sigma C6198), VCAM1 (Abcam ab134047), F4/80 (BD 565411), CD206 (CST 24595), GSDMD (Sigma G7422), Ki67 (Abcam ab16667), MMP2 (Abcam ab92536), PLIN2 (Proteintech 15294-1-AP), TFEB (Bethyl Laboratories A303-673A), LAMP2A (Abcam ab18528), LAMP1 (BD 553792), LC3 (CST 12741S).\u003c/p\u003e \u003cp\u003eSecondary antibody for immunofluorescence (1:500 dilution): Donkey anti-Mice IgG (H\u0026thinsp;+\u0026thinsp;L) Secondary Antibody, Alexa Fluor\u0026reg; 488 conjugate (Thermo Fisher A-21202); Donkey anti-Rabbit IgG (H\u0026thinsp;+\u0026thinsp;L) Secondary Antibody, Alexa Fluor\u0026reg; 488 conjugate (Thermo Fisher A21206); Donkey anti-Mice IgG (H\u0026thinsp;+\u0026thinsp;L) Secondary Antibody, Alexa Fluor\u0026reg; 555 conjugate (Thermo Fisher A-31570); Donkey anti-Rabbit IgG (H\u0026thinsp;+\u0026thinsp;L) Secondary Antibody, Alexa Fluor\u0026reg; 555 conjugate (Thermo Fisher A-31572); Donkey anti-Rat IgG (H\u0026thinsp;+\u0026thinsp;L) Highly Cross-Adsorbed, Alexa Fluor 594 (Thermo Fisher A21209); Donkey anti-Rabbit IgG (H\u0026thinsp;+\u0026thinsp;L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor\u0026trade; Plus 647 (Thermo Fisher A32795TR); Donkey anti-Rat IgG (H\u0026thinsp;+\u0026thinsp;L) Highly Cross-Adsorbed Secondary Antibody, Alexa Fluor\u0026trade; 647 (Thermo Fisher A78947).\u003c/p\u003e \u003cp\u003eReagents: Green FLICA Caspase-1 Assay Kit (Immunochemistry Technologies #98), In Situ Cell Death Detection Kit (Sigma 11684795910), Sirius Red (Sigma 365548-5g), Fast green (Sigma F7252-5g), Hematoxylin and Eosin staining kit (Teomics HAE- 1), Oil red O (VWR 135140-100G), Bodipy (Thermo Fisher D3922).\u003c/p\u003e \u003c/div\u003e\n\u003ch3\u003eMice\u003c/h3\u003e\n\u003cp\u003e All procedures involving animals were conducted in accordance with protocols approved by the University of Houston Institutional Review Board (IRB) and Institutional Animal Care and Use Committee (IACUC). Mice were maintained in a specific pathogen-free, temperature-regulated animal facility on a 12 h light/12 h dark schedule, with free access to water and a standard chow diet (PicoLab\u0026reg; Rodent Diet 20; 5053) unless noted otherwise.\u003c/p\u003e \u003cp\u003e \u003cb\u003eGeneration of VSMC-specific\u003c/b\u003e \u003cb\u003eNlrp3\u003c/b\u003e \u003cb\u003eKnock-in mice\u003c/b\u003e\u003c/p\u003e \u003cp\u003e \u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003eL351PneoR\u003c/sup\u003e mice (JAX:017970) harbor a Cre-conditional \u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003eL351P\u003c/sup\u003e allele in the absence of Cre; the neoR cassette disrupts \u003cem\u003eNlrp3\u003c/em\u003e expression, whereas Cre-mediated recombination restores expression of an \u003cem\u003eNlrp3\u003c/em\u003e transcript carrying the L351P mutation in Cre-specific tissues. Myh11-Cre transgenic mice (JAX:007742) were obtained from The Jackson Laboratory. To generate a VSMC-specific gain-of-function (GOF) model, \u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003eL351PneoR\u003c/sup\u003e mice were crossed with Myh11-Cre mice to produce \u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003eL351P/+/Myh11\u0026minus;Cre\u003c/sup\u003e (\u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003eSMKI\u003c/sup\u003e) mice and Cre-negative littermate \u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003eL351P/+/WT\u003c/sup\u003e (\u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003ectrl\u003c/sup\u003e) controls. Both \u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003eSMKI\u003c/sup\u003e and littermate control \u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003ectrl\u003c/sup\u003e mice were heterozygous for the \u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003eL351P/+\u003c/sup\u003e allele. Genotypes were confirmed by PCR using primers and conditions provided by the vendor.\u003c/p\u003e\n\u003ch3\u003ePartial carotid ligation surgery\u003c/h3\u003e\n\u003cp\u003ePartial carotid ligation was performed in 6-month-old male \u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003eSMKI\u003c/sup\u003e mice and \u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003ectrl\u003c/sup\u003e littermates. The left carotid artery was subjected to partial ligation, while the right side remained unligated and was used as the control vessel \u003csup\u003e\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e,\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e,\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e\u003c/sup\u003e. Following surgery, mice were maintained on a Paigen\u0026rsquo;s diet (Research Diets, D12336) containing 35% kcal from fat and 1.25% cholesterol for 4 weeks. Mice were anesthetized and euthanized by cervical dislocation, and bilateral carotid arteries were excised for immunohistochemistry and immunofluorescence. Tissues were embedded in Tissue-Tek O.C.T., snap-frozen in liquid nitrogen, stored at \u0026minus;\u0026thinsp;80\u0026deg;C, and cryosectioned at 8 \u0026micro;m.\u003c/p\u003e\n\u003ch3\u003eImmunofluorescence staining\u003c/h3\u003e\n\u003cp\u003eFrozen sections were briefly equilibrated at room temperature and air-dried for no longer than 15 min. Sections were then fixed in freshly prepared 4% paraformaldehyde for 15 min at room temperature, followed by rinsing in PBS. For simultaneous permeabilization and blocking, sections were incubated for 1 h at room temperature in PBS containing 5% BSA and 0.3% Triton X-100. Primary antibodies (as indicated) were applied and incubated overnight at 4\u0026deg;C. After washing, sections were incubated with species-matched Alexa Fluor\u0026ndash;conjugated secondary antibodies (488/555/647) for 1 h at room temperature. Nuclei were counterstained with DAPI for 15 min and slides were mounted using an antifade mounting medium.\u003c/p\u003e \u003cp\u003eFluorescence images were acquired using an Olympus IX73 imaging system under identical exposure and acquisition parameters across groups. Quantification was performed in Image-Pro Plus 6.0 by measuring mean fluorescence density (as applicable) or calculating Pearson\u0026rsquo;s correlation coefficient (PCC) for protein colocalization within the carotid intima and media. For each carotid artery, three consecutive serial sections were stained and analyzed for each marker, and values from the three sections were averaged to generate a single measurement per animal.\u003c/p\u003e \u003cp\u003eFor regional analysis, unligated arteries were quantified in the medial layer only, identified as the continuous α-SMA\u0026ndash;positive band. In ligated arteries, α-SMA\u0026ndash;positive VSMCs in both the neointima (migrated VSMCs) and the media were included. Specificity was assessed using adjacent sections incubated with matched isotype IgG at the same concentration in place of primary antibodies; no appreciable nonspecific background signal was detected. Potential elastin autofluorescence in the AF488 channel under low-signal conditions was minimized by imaging α-SMA with strong FITC signals (\u0026le;\u0026thinsp;50 ms exposure), while most targets were collected in the AF555 or AF647 channels, thereby avoiding interference from elastin-derived fluorescence \u003csup\u003e\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e\n\u003ch3\u003eFLICA analysis of caspase-1 activation\u003c/h3\u003e\n\u003cp\u003eFrozen sections were equilibrated to room temperature and air-dried for \u0026le;\u0026thinsp;15 min. Without fixation, sections were incubated with the FLICA reagent together with Hoechst 33342 (FLICA Assay Kit) for 1.5 h at 37\u0026deg;C. Slides were then washed three times in pre-warmed assay buffer (10 min each, 37\u0026deg;C). The FLICA-derived green fluorescence was captured using an Olympus IX73 imaging system \u003csup\u003e\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e,\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cdiv id=\"Sec8\" class=\"Section2\"\u003e \u003ch2\u003eTUNEL staining\u003c/h2\u003e \u003cp\u003eFrozen tissue sections were fixed with freshly prepared 4% paraformaldehyde for 20 min at room temperature, followed by washing in PBS for 30 min. Sections were then permeabilized in 0.1% Triton X-100/0.1% sodium citrate for 2 min on ice. TUNEL reaction mixture was freshly prepared and 50 \u0026micro;L was applied to each section, followed by incubation for 60 min at 37\u0026deg;C in a humidified chamber protected from light; negative controls were incubated with Label Solution lacking enzyme. After incubation, slides were rinsed three times with PBS and imaged by fluorescence microscopy using FITC settings (Ex 450\u0026ndash;500 nm; Em 515\u0026ndash;565 nm) \u003csup\u003e\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003c/div\u003e\n\u003ch3\u003eSirius red and fast green staining\u003c/h3\u003e\n\u003cp\u003eFrozen sections were fixed in Kahle\u0026rsquo;s fixative for 15 min at room temperature, rinsed with PBS, and stained for 60 min at room temperature in a picric acid\u0026ndash;based Sirius Red/Fast Green solution (0.1% Sirius Red and 0.1% Fast Green in saturated aqueous picric acid). Slides were then rinsed twice in acidified water (0.1 N HCl in ddH₂O; 1 min each). Sections were dehydrated through two changes of 100% ethanol and cleared in xylene prior to coverslipping with mounting medium. Images were acquired immediately using an Olympus IX73 imaging system \u003csup\u003e\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e\n\u003ch3\u003eH\u0026E staining\u003c/h3\u003e\n\u003cp\u003eHematoxylin and eosin staining was performed using a commercial kit (Teomics, HAE-1). Briefly, frozen sections were fixed in 4% paraformaldehyde for 15 min at room temperature and rinsed with distilled water. Sections were stained with Mayer\u0026rsquo;s hematoxylin for 5 min, washed twice in distilled water, and briefly blued using bluing reagent (10\u0026ndash;15 s) followed by two additional water rinses. Slides were then dipped in absolute ethanol to remove residual water, counterstained with Eosin Y for 2\u0026ndash;3 min and rinsed in absolute ethanol. After clearing, sections were mounted with synthetic resin and imaged on an Olympus IX73 microscope \u003csup\u003e\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e,\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cdiv id=\"Sec11\" class=\"Section2\"\u003e \u003ch2\u003eOil red O staining\u003c/h2\u003e \u003cp\u003eFrozen sections (8 \u0026micro;m) were allowed to air-dry and fixed in 4% PFA for 15 min. Slides were then rinsed in distilled water (three changes) and immersed in distilled water for 20 min. To minimize aqueous carryover, sections briefly dipped in 60% isopropanol for 1 min prior to staining. Sections were incubated with freshly prepared Oil Red O working solution for 30 min, rinsed in 60% isopropanol for 2 min, and washed twice with distilled water. Slides were mounted with mounting medium and imaged immediately using an Olympus IX73 imaging system \u003csup\u003e\u003cspan citationid=\"CR22\" class=\"CitationRef\"\u003e22\u003c/span\u003e,\u003cspan citationid=\"CR23\" class=\"CitationRef\"\u003e23\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec12\" class=\"Section2\"\u003e \u003ch2\u003eBODIPY 493/503 staining\u003c/h2\u003e \u003cp\u003eNeutral lipid droplets were visualized using BODIPY 493/503 (Invitrogen, D3922). Frozen sections were fixed in 4% paraformaldehyde for 10 min and rinsed with PBS-T. Sections were then incubated for 1 h at room temperature with BODIPY 493/503 (40 \u0026micro;g/mL) together with DAPI diluted in PBS-T. After washing in PBS-T, slides were mounted with Mowiol and imaged immediately using an Olympus IX73 imaging system \u003csup\u003e\u003cspan citationid=\"CR24\" class=\"CitationRef\"\u003e24\u003c/span\u003e,\u003cspan citationid=\"CR25\" class=\"CitationRef\"\u003e25\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec13\" class=\"Section2\"\u003e \u003ch2\u003eStatistical analysis\u003c/h2\u003e \u003cp\u003eAll quantitative results are reported as mean\u0026thinsp;\u0026plusmn;\u0026thinsp;SEM. Given the small cohort sizes (N\u0026thinsp;\u0026lt;\u0026thinsp;10) and the lack of normality in our datasets, nonparametric tests were applied throughout. Comparisons among three or more groups were performed using the Kruskal\u0026ndash;Wallis test with Dunn\u0026rsquo;s post hoc multiple-comparisons correction. For two-group comparisons, the Mann\u0026ndash;Whitney U test was used. Analyses were conducted in GraphPad Prism (version 9.0; GraphPad Software, USA). A two-sided P value\u0026thinsp;\u0026lt;\u0026thinsp;0.05 was considered statistically significant. Sample sizes were selected based on prior publications and pilot data to provide adequate sensitivity for detecting biologically relevant effects. Data was excluded only for pre-specified reasons, including sample contamination, technical failure, or clear measurement artifacts; outliers were handled according to predefined criteria. Investigators were blinded to group assignment during experimental procedures and outcome quantification to reduce bias and ensure objective interpretation.\u003c/p\u003e \u003c/div\u003e"},{"header":"Results","content":"\u003cp\u003e \u003cb\u003eVSMC-specific\u003c/b\u003e \u003cb\u003eNlrp3\u003c/b\u003e \u003cb\u003egain-of-function mutation activates the NLRP3 inflammasome in vivo.\u003c/b\u003e\u003c/p\u003e \u003cp\u003eIn our recent work, we showed that carotid partial ligation injury under hypercholesterolemic conditions activates the NLRP3 inflammasome in VSMCs, and that global \u003cem\u003eNlrp3\u003c/em\u003e deficiency attenuates injury-induced inflammasome activation and intimal hyperplasia \u003csup\u003e\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e\u003c/sup\u003e. To directly define the contribution of VSMC-intrinsic NLRP3 to pathological vascular remodeling, we generated a VSMC-specific \u003cem\u003eNlrp3\u003c/em\u003e knock-in model by crossing \u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003eL351PneoR\u003c/sup\u003e mice with Myh11-Cre mice, yielding \u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003eL351P/+/Myh11\u0026minus;Cre\u003c/sup\u003e (\u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003eSMKI\u003c/sup\u003e) mice and littermate \u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003eL351P/+/WT\u003c/sup\u003e (\u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003ectrl\u003c/sup\u003e) controls (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eA). The L351P substitution (from leucine to proline at residue 351) corresponds to the human L353P mutation associated with cryopyrin-associated periodic syndromes (CAPS) and is predicted to enhance NLRP3 inflammasome assembly/activation through altered interdomain or protein\u0026ndash;protein interactions \u003csup\u003e\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eWe subjected \u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003eSMKI\u003c/sup\u003e and \u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003ectrl\u003c/sup\u003e mice to partial carotid ligation and Paigen\u0026rsquo;s diet to induce intimal hyperplasia \u003csup\u003e\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e,\u003cspan citationid=\"CR20\" class=\"CitationRef\"\u003e20\u003c/span\u003e,\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e\u003c/sup\u003e, then assessed inflammasome activation in ligated and contralateral unligated arteries. NLRP3 immunostaining was increased after ligation in both genotypes, and this injury-induced upregulation was significantly greater in \u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003eSMKI\u003c/sup\u003e arteries; by contrast, NLRP3 levels were comparable between genotypes in unligated arteries (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eB\u0026ndash;C). Importantly, FLICA labeling (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eD\u0026ndash;E) and cleaved caspase-1 staining (Fig.\u0026nbsp;\u003cspan refid=\"Fig1\" class=\"InternalRef\"\u003e1\u003c/span\u003eF\u0026ndash;G) demonstrated that VSMC \u003cem\u003eNlrp3\u003c/em\u003e GOF was sufficient to induce caspase-1 activation even in unligated arteries and further amplified ligation-induced caspase-1 activation in injured arteries. Together, these data establish a VSMC-intrinsic model of enhanced NLRP3\u0026ndash;caspase-1 activity in the injured artery. This heightened inflammasome activation provides a mechanistic basis for downstream inflammatory signaling and vascular wall immune cell recruitment during remodeling.\u003c/p\u003e \u003cp\u003e \u003cb\u003eVSMC\u003c/b\u003e \u003cb\u003eNlrp3\u003c/b\u003e \u003cb\u003egain-of-function exacerbates vascular inflammation after injury\u003c/b\u003e\u003c/p\u003e \u003cp\u003eVascular inflammation is a hallmark of intimal hyperplasia and is characterized by increased adhesion molecule expression and recruitment of inflammatory cells \u003csup\u003e\u003cspan citationid=\"CR26\" class=\"CitationRef\"\u003e26\u003c/span\u003e\u003c/sup\u003e. We therefore examined whether VSMC \u003cem\u003eNlrp3\u003c/em\u003e GOF enhances inflammatory activation after injury. Consistent with our prior observations \u003csup\u003e\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e\u003c/sup\u003e, partial ligation markedly increased VCAM-1 expression in VSMC of the vessel wall, and this response was significantly greater in \u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003eSMKI\u003c/sup\u003e mice, with the most prominent signal localized to the neointimal region (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eA\u0026ndash;B). In parallel, immunostaining for the pan-macrophage marker F4/80 (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eC\u0026ndash;D) revealed increased macrophage accumulation in ligated arteries, which was further amplified in \u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003eSMKI\u003c/sup\u003e mice. Staining for M2-polarized macrophage marker CD206 (Fig.\u0026nbsp;\u003cspan refid=\"Fig2\" class=\"InternalRef\"\u003e2\u003c/span\u003eE\u0026ndash;F) also increased after injury and was elevated to a greater extent in ligated arteries from \u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003eSMKI\u003c/sup\u003e mice. Together, these results support that VSMC-intrinsic NLRP3 hyperactivation potentiates injury-induced VCAM-1 upregulation and promotes macrophage accumulation within the remodeling vessel wall, thereby exacerbating vascular inflammation. Thus, VSMC NLRP3 hyperactivation amplifies endothelial/vascular inflammatory activation and creates a permissive environment for leukocyte adhesion and accumulation in the lesion.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cdiv id=\"Sec15\" class=\"Section2\"\u003e \u003ch2\u003eVSMC Nlrp3 gain-of-function enhances GSDMD upregulation and cell death after vascular injury\u003c/h2\u003e \u003cp\u003eGiven the canonical linkage between NLRP3\u0026ndash;caspase-1 activation and GSDMD-mediated pyroptotic signaling, we next assessed GSDMD and cell death in injured arteries. Consistent with our previous study \u003csup\u003e\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e\u003c/sup\u003e, partial ligation induced VSMC GSDMD upregulation in the vessel wall; notably, this increase was significantly greater in \u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003eSMKI\u003c/sup\u003e mice (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eA\u0026ndash;B). Moreover, TUNEL staining showed that partial ligation-induced cell death was further increased by VSMC \u003cem\u003eNlrp3\u003c/em\u003e GOF (Fig.\u0026nbsp;\u003cspan refid=\"Fig3\" class=\"InternalRef\"\u003e3\u003c/span\u003eC\u0026ndash;D). These findings are consistent with activation of the NLRP3\u0026ndash;caspase-1\u0026ndash;GSDMD axis in vivo. These findings link VSMC NLRP3 hyperactivation to activation of the caspase-1\u0026ndash;GSDMD effector arm and increased cell death within the remodeling vessel wall.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec16\" class=\"Section2\"\u003e \u003ch2\u003eVSMC Nlrp3 gain-of-function promotes VSMC proliferation/migration and aggravates intimal hyperplasia\u003c/h2\u003e \u003cp\u003eExcessive VSMC proliferation and migration into the intima are central drivers of intimal hyperplasia during vascular remodeling \u003csup\u003e\u003cspan citationid=\"CR1\" class=\"CitationRef\"\u003e1\u003c/span\u003e,\u003cspan citationid=\"CR27\" class=\"CitationRef\"\u003e27\u003c/span\u003e\u003c/sup\u003e. Ki-67 is expressed in all active phases of the cell cycle and is widely used to quantify proliferating VSMCs in vascular lesions \u003csup\u003e\u003cspan citationid=\"CR28\" class=\"CitationRef\"\u003e28\u003c/span\u003e\u003c/sup\u003e. We observed that partial ligation increased the number of Ki-67-positive VSMCs in the vessel wall, and this proliferative response was significantly enhanced in \u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003eSMKI\u003c/sup\u003e mice (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eA\u0026ndash;B). We next assessed VSMC migratory remodeling by examining MMP-2, a key mediator of extracellular matrix degradation and VSMC migration \u003csup\u003e\u003cspan citationid=\"CR29\" class=\"CitationRef\"\u003e29\u003c/span\u003e\u003c/sup\u003e. Strikingly, VSMC \u003cem\u003eNlrp3\u003c/em\u003e GOF increased MMP-2 expression even in unligated arteries and further amplified ligation-induced MMP-2 upregulation in injured arteries (Fig.\u0026nbsp;\u003cspan refid=\"Fig4\" class=\"InternalRef\"\u003e4\u003c/span\u003eC\u0026ndash;D).\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003cp\u003eWe then evaluated structural remodeling endpoints. Sirius red staining demonstrated robust collagen deposition after ligation; however, total collagen accumulation was not further increased by VSMC \u003cem\u003eNlrp3\u003c/em\u003e GOF (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eA, \u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eC). In contrast, H\u0026amp;E staining and morphometric analysis showed that ligation induced substantial intimal hyperplasia in \u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003ectrl\u003c/sup\u003e mice, and this response was significantly exacerbated in \u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003eSMKI\u003c/sup\u003e mice, as reflected by increased intimal area and elevated intima-to-media ratio (Fig.\u0026nbsp;\u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eB, \u003cspan refid=\"Fig5\" class=\"InternalRef\"\u003e5\u003c/span\u003eD\u0026ndash;E). Together, these data indicate that VSMC NLRP3 hyperactivation enhances proliferative/migratory remodeling and markedly worsens injury-induced intimal hyperplasia.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec17\" class=\"Section2\"\u003e \u003ch2\u003eVSMC Nlrp3 gain-of-function accelerates VSMC-to-foam cell transition\u003c/h2\u003e \u003cp\u003eVSMC-to-foam cell transition is a lipid-driven phenotypic switch involving metabolic reprogramming, and lineage-tracing/single-cell studies indicate that a substantial fraction of foam cells within mouse and human plaques can originate from VSMCs \u003csup\u003e\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e,\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u003c/sup\u003e. We therefore tested whether VSMC \u003cem\u003eNlrp3\u003c/em\u003e GOF affects lipid accumulation within the injured vessel wall. Compared with controls, \u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003eSMKI\u003c/sup\u003e arteries displayed significantly greater lipid deposition after injury, as demonstrated by Oil Red O staining (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eA\u0026ndash;B) and BODIPY staining (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eC\u0026ndash;D). Consistently, the lipid droplet coat protein PLIN2 was increased to a greater extent in \u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003eSMKI\u003c/sup\u003e lesions (Fig.\u0026nbsp;\u003cspan refid=\"Fig6\" class=\"InternalRef\"\u003e6\u003c/span\u003eE\u0026ndash;F). These results demonstrate that VSMC NLRP3 hyperactivation promotes VSMC lipid loading and foam cell\u0026ndash;like phenotypic transition in vivo. The enhanced lipid accumulation and PLIN2 induction suggest that NLRP3 hyperactivation promotes a metabolic shift in VSMCs toward lipid storage and foam cell\u0026ndash;like phenotype.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e \u003cdiv id=\"Sec18\" class=\"Section2\"\u003e \u003ch2\u003eVSMC Nlrp3 gain-of-function impairs TFEB-mediated autophagy\u0026ndash;lysosome signaling\u003c/h2\u003e \u003cp\u003eTFEB is a master transcriptional regulator of autophagy\u0026ndash;lysosome pathways, coordinating lysosomal biogenesis, autophagosome formation, and cargo degradation \u003csup\u003e\u003cspan additionalcitationids=\"CR31\" citationid=\"CR30\" class=\"CitationRef\"\u003e30\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR32\" class=\"CitationRef\"\u003e32\u003c/span\u003e\u003c/sup\u003e. Our prior study showed that TFEB signaling is suppressed in ligated carotid arteries \u003csup\u003e\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e\u003c/sup\u003e. Consistent with this, ligation reduced TFEB expression in VSMCs, and this decrease was significantly more pronounced in \u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003eSMKI\u003c/sup\u003e arteries (Fig.\u0026nbsp;\u003cspan refid=\"Fig7\" class=\"InternalRef\"\u003e7\u003c/span\u003eA\u0026ndash;B), indicating that VSMC NLRP3 hyperactivation further suppresses TFEB during vascular remodeling. We next assessed lysosomal and autophagy markers. LAMP2A, a key receptor required for chaperone-mediated autophagy \u003csup\u003e\u003cspan citationid=\"CR33\" class=\"CitationRef\"\u003e33\u003c/span\u003e\u003c/sup\u003e, was increased by ligation in this dataset (in contrast to our previous observation \u003csup\u003e\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e\u003c/sup\u003e). Notably, VSMC \u003cem\u003eNlrp3\u003c/em\u003e gain-of-function counteracted this ligation-induced LAMP2A increase and reduced LAMP2A levels in VSMCs (Fig.\u0026nbsp;\u003cspan refid=\"Fig7\" class=\"InternalRef\"\u003e7\u003c/span\u003eC\u0026ndash;D). In addition, \u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003eSMKI\u003c/sup\u003e arteries exhibited greater impairment of lysosome/autophagy markers, including reduced LAMP1 (Fig.\u0026nbsp;\u003cspan refid=\"Fig7\" class=\"InternalRef\"\u003e7\u003c/span\u003eE\u0026ndash;F) and decreased LC3 signal (Fig.\u0026nbsp;\u003cspan refid=\"Fig7\" class=\"InternalRef\"\u003e7\u003c/span\u003eG\u0026ndash;H) compared with \u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003ectrl\u003c/sup\u003e arteries after injury. Collectively, these data support that VSMC NLRP3 gain-of-function disrupts TFEB-associated autophagy\u0026ndash;lysosome homeostasis during injury-induced vascular remodeling.\u003c/p\u003e \u003cp\u003e \u003c/p\u003e \u003c/div\u003e"},{"header":"Discussion","content":"\u003cp\u003eIn this study, we provide direct in vivo evidence that VSMC-intrinsic NLRP3 hyperactivation is sufficient to drive maladaptive vascular remodeling and markedly worsen intimal hyperplasia under hypercholesterolemic injury conditions. Using a VSMC-specific Nlrp3 gain-of-function knock-in model, we bypass the long-standing ambiguity inherent to systemic loss-of-function approaches and directly assign causality to VSMCs as the initiating and amplifying compartment in inflammasome-dependent lesion progression. Our data support a mechanistic cascade in which enhanced NLRP3\u0026ndash;caspase-1 signaling in VSMCs augments vascular inflammation, engages the caspase-1\u0026ndash;GSDMD effector arm, leading to increased cell death, promotes proliferative and migratory remodeling, and accelerates lipid loading and a VSMC-to\u0026ndash;foam cell\u0026ndash;like phenotypic transition, culminating in exacerbated neointimal growth.\u003c/p\u003e \u003cp\u003eRecent studies have leveraged gain-of-function NLRP3 knock-in (KI) mice to model cryopyrin-associated periodic syndromes (CAPS) and to dissect how inflammasome hyperactivation drives tissue pathology. Seminal work by Hoffman and colleagues established KI strains carrying CAPS-linked mutations (e.g., A352V and L353P) and showed that these variants can trigger systemic inflammation and early mortality when expressed in myeloid lineages \u003csup\u003e\u003cspan citationid=\"CR19\" class=\"CitationRef\"\u003e19\u003c/span\u003e\u003c/sup\u003e. Since then, additional CAPS-relevant NLRP3 KI models\u0026mdash;including D301N, R258W, and others\u0026mdash;have been applied across diverse organ systems and cell types to reveal how cell-intrinsic NLRP3 hyperactivation shapes inflammation and disease phenotypes \u003csup\u003e\u003cspan citationid=\"CR34\" class=\"CitationRef\"\u003e34\u003c/span\u003e,\u003cspan citationid=\"CR35\" class=\"CitationRef\"\u003e35\u003c/span\u003e\u003c/sup\u003e. Although these models have been highly informative and increasingly adopted beyond classic autoinflammatory contexts, the potential contribution of cardiovascular-resident cells, particularly endothelial cells and vascular smooth muscle cells (VSMCs), to NLRP3-driven CAPS-like pathology and vascular remodeling remains poorly defined. Addressing this gap, we provide the first direct evidence that smooth muscle\u0026ndash;restricted NLRP3 gain-of-function (L351P KI) is sufficient to activate the inflammasome program in vivo and to exacerbate injury-driven vascular remodeling. Notably, VSMC Nlrp3 gain-of-function increased inflammasome activation not only after partial carotid ligation under hypercholesterolemia, but also detectably in unligated arteries, as indicated by elevated FLICA labeling and cleaved caspase-1 staining. This suggests that VSMC inflammasome hyperactivation can establish a \u0026ldquo;primed\u0026rdquo; pro-inflammatory state that lowers the activation threshold of the vessel wall, thereby sensitizing arteries to subsequent hemodynamic or metabolic stress. Following injury, this primed state translated into a markedly amplified caspase-1 response, enhanced inflammatory activation and macrophage accumulation, and accelerated neointimal growth. Together, these findings support a model in which VSMC-intrinsic NLRP3 hyperactivation is an upstream driver, rather than a passive byproduct, of the inflammatory microenvironment that fuels pathological vascular remodeling. Future work should determine whether other CAPS-linked NLRP3 variants similarly reprogram VSMC function, define the downstream mediators coupling VSMC inflammasome activation to lesion progression, and test whether targeting VSMC NLRP3 signaling can mitigate vascular pathology in relevant disease settings.\u003c/p\u003e \u003cp\u003eConsistent with this, VSMC NLRP3 hyperactivation significantly intensified vascular inflammatory activation and immune cell accumulation. VCAM-1 upregulation within the vessel wall was increased in \u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003eSMKI\u003c/sup\u003e arteries, particularly within the neointimal region, accompanied by greater macrophage accumulation (F4/80\u003csup\u003e+\u003c/sup\u003e) and increased CD206\u003csup\u003e+\u003c/sup\u003e macrophage staining after injury. Increased VCAM-1 provides a plausible molecular link between VSMC inflammasome activation and leukocyte adhesion and retention within lesions, thereby amplifying local inflammatory signaling. Elevated macrophage accumulation (F4/80+) indicates significant infiltration within the lesion, while increased CD206\u0026thinsp;+\u0026thinsp;expression reflects a polarization toward a 'repair-associated' phenotype. These cells support lesion remodeling through growth factor production, matrix remodeling, and complex effects on lipid handling depending on context \u003csup\u003e\u003cspan citationid=\"CR36\" class=\"CitationRef\"\u003e36\u003c/span\u003e,\u003cspan citationid=\"CR37\" class=\"CitationRef\"\u003e37\u003c/span\u003e\u003c/sup\u003e. Together, these findings place VSMC NLRP3 activity upstream of a permissive inflammatory niche, poised to accelerate lesion development through both immune-dependent and immune-independent mechanisms.\u003c/p\u003e \u003cp\u003eWe further demonstrate that VSMC NLRP3 hyperactivation activates the caspase-1\u0026ndash;GSDMD effector axis and is associated with increased cell death within the remodeling vessel wall. In \u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003eSMKI\u003c/sup\u003e arteries, ligation elicited greater GSDMD upregulation accompanied by increased TUNEL positivity, consistent with enhanced inflammasome-linked cellular injury. Importantly, in the setting of intimal hyperplasia, cell death can be pro-remodeling rather than protective: pyroptosis-associated membrane permeabilization and release of inflammatory mediators and danger signals can amplify paracrine activation of neighboring vascular cells, promote chemokine/adhesion molecule expression, and trigger compensatory VSMC proliferation and migration. In parallel, inflammasome-derived IL-1 family cytokines directly support VSMC activation states that favor migratory and proliferative remodeling \u003csup\u003e\u003cspan additionalcitationids=\"CR39\" citationid=\"CR38\" class=\"CitationRef\"\u003e38\u003c/span\u003e\u0026ndash;\u003cspan citationid=\"CR40\" class=\"CitationRef\"\u003e40\u003c/span\u003e\u003c/sup\u003e. Notably, our recent work further indicates that GSDMD can promote platelet-derived growth factor-BB (PDGF-BB)\u0026ndash;induced VSMC proliferation, migration, and inflammation independent of overt cell death \u003csup\u003e\u003cspan citationid=\"CR18\" class=\"CitationRef\"\u003e18\u003c/span\u003e\u003c/sup\u003e, highlighting a non-lytic remodeling function for this pathway. Together, these findings support a model in which NLRP3\u0026ndash;caspase-1\u0026ndash;GSDMD signaling accelerates neointimal growth through both inflammatory injury\u0026ndash;driven feed-forward loops and cell-intrinsic, pro-remodeling effects on VSMC behavior.\u003c/p\u003e \u003cp\u003eIn line with this model, we observed that VSMC Nlrp3 gain-of-function robustly enhanced the proliferative and migratory programs that drive neointimal expansion. \u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003eSMKI\u003c/sup\u003e arteries exhibited increased Ki-67\u0026ndash;positive VSMCs after ligation and elevated MMP-2 expression, with a notable increase even in unligated arteries. These findings are consistent with the established paradigm that injury-induced phenotypic switching enables VSMCs to proliferate, degrade extracellular matrix via MMPs, and migrate into the intima to form neointimal lesions \u003csup\u003e\u003cspan citationid=\"CR41\" class=\"CitationRef\"\u003e41\u003c/span\u003e\u003c/sup\u003e. Importantly, these molecular and cellular changes translated into clear structural consequences: \u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003eSMKI\u003c/sup\u003e mice developed significantly greater intimal hyperplasia, reflected by increased intimal area and a higher intima-to-media ratio\u0026mdash;standard morphometric endpoints tightly linked to restenosis severity \u003csup\u003e\u003cspan citationid=\"CR42\" class=\"CitationRef\"\u003e42\u003c/span\u003e,\u003cspan citationid=\"CR43\" class=\"CitationRef\"\u003e43\u003c/span\u003e\u003c/sup\u003e. Although collagen deposition increased after injury, VSMC \u003cem\u003eNlrp3\u003c/em\u003e gain-of-function did not further augment total collagen accumulation, suggesting that the predominant impact of VSMC inflammasome hyperactivation in this setting is cellular expansion and lesion architecture, rather than generalized fibrosis. This distinction is clinically relevant because VSMC accumulation and neointimal cellularity, more than collagen content per se, are major determinants of luminal narrowing and restenosis risk.\u003c/p\u003e \u003cp\u003eBeyond lesion size, our findings extend VSMC inflammasome biology into the domain of lipid-driven phenotypic switching. We show that VSMC \u003cem\u003eNlrp3\u003c/em\u003e gain-of-function significantly increased vascular lipid deposition (Oil Red O and BODIPY staining) and elevated PLIN2 expression in injured arteries, supporting accelerated VSMC lipid loading and foam cell\u0026ndash;like transition. This observation is particularly important given accumulating evidence that VSMCs contribute substantially to foam cell populations in atherosclerotic plaques and can acquire macrophage-like transcriptional programs that complicate lesion biology and therapeutic targeting \u003csup\u003e\u003cspan citationid=\"CR8\" class=\"CitationRef\"\u003e8\u003c/span\u003e,\u003cspan citationid=\"CR9\" class=\"CitationRef\"\u003e9\u003c/span\u003e\u003c/sup\u003e. Functionally, VSMC-to-foam cell transition is not a benign lipid-storage state: it is associated with loss of canonical contractile identity, impaired matrix homeostasis, and reduced plaque-stabilizing functions of VSMCs, while promoting a pro-inflammatory, protease-rich, and stress-vulnerable phenotype that can increase necrotic core formation and lesion complexity \u003csup\u003e\u003cspan citationid=\"CR44\" class=\"CitationRef\"\u003e44\u003c/span\u003e\u003c/sup\u003e. In addition, lipid-laden VSMCs may be more prone to cell death and defective efferocytosis, thereby amplifying inflammatory signaling and contributing to the expansion of acellular/necrotic regions within lesions \u003csup\u003e\u003cspan citationid=\"CR45\" class=\"CitationRef\"\u003e45\u003c/span\u003e\u003c/sup\u003e. Consistent with this concept, an in vitro/in vivo study demonstrated that NLRP3 inflammasome activation promotes foam cell formation in human VSMCs and atherogenesis via HMGB1 \u003csup\u003e46\u003c/sup\u003e. Thus, our data suggest that inflammasome hyperactivation within VSMCs is sufficient to bias VSMCs toward a lipid-storing, foam-like phenotype in vivo, providing a mechanistic link between inflammatory danger sensing and metabolic remodeling that can accelerate plaque progression and destabilizing features, beyond simply increasing lesion burden.\u003c/p\u003e \u003cp\u003eMechanistically, we observed that VSMC NLRP3 hyperactivation was accompanied by suppression of TFEB and broad impairment of autophagy\u0026ndash;lysosome markers (LAMP1, LAMP2A, LC3) during vascular remodeling. These results suggest that lysosomal quality control is not simply a downstream bystander of injury, but a vulnerable node that is further destabilized by excessive VSMC inflammasome activity. Because lysosome\u0026ndash;autophagy pathways are central to lipid droplet turnover and cellular stress resolution, their impairment provides a plausible explanation for the increased lipid accumulation and PLIN2 induction observed in \u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003eSMKI\u003c/sup\u003e lesions. Moreover, lysosomal dysfunction can reinforce inflammation by promoting the accumulation of damaged organelles and endogenous danger signals, thereby creating a feed-forward loop that sustains, and can further amplify inflammasome signaling \u003csup\u003e\u003cspan citationid=\"CR47\" class=\"CitationRef\"\u003e47\u003c/span\u003e\u003c/sup\u003e.\u003c/p\u003e \u003cp\u003eImportantly, TFEB suppression provides a unifying mechanism that extends beyond lipid handling. In our previous study, TFEB activation/overexpression restrained VSMC proliferation and migration, whereas TFEB silencing promoted these pro-remodeling behaviors \u003csup\u003e\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e,\u003cspan citationid=\"CR48\" class=\"CitationRef\"\u003e48\u003c/span\u003e,\u003cspan citationid=\"CR49\" class=\"CitationRef\"\u003e49\u003c/span\u003e\u003c/sup\u003e. Thus, NLRP3 hyperactivation\u0026ndash;induced TFEB downregulation may contribute not only to VSMC foam cell\u0026ndash;like transition, but also to the heightened proliferative and migratory remodeling that drives neointimal expansion. In addition, TFEB overexpression has been linked to enhanced antioxidant defenses and anti-inflammatory effects in endothelial cells \u003csup\u003e\u003cspan citationid=\"CR50\" class=\"CitationRef\"\u003e50\u003c/span\u003e\u003c/sup\u003e, offering a plausible pathway by which TFEB loss could further amplify vascular inflammation and injury responses in the lesion microenvironment.\u003c/p\u003e \u003cp\u003eOne unexpected observation was that LAMP2A increased in \u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003ectrl\u003c/sup\u003e arteries after ligation in this dataset, which differs from our prior report showing reduced LAMP2A in ligated arteries from \u003cem\u003ewild type\u003c/em\u003e mice \u003csup\u003e\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e\u003c/sup\u003e. We interpret this injury-induced upregulation of LAMP2A as a potential compensatory response aimed at enhancing chaperone-mediated autophagy and restoring proteostasis under vascular stress. In contrast, LAMP2A was reduced in ligated arteries from \u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003eSMKI\u003c/sup\u003e mice, indicating that VSMC \u003cem\u003eNlrp3\u003c/em\u003e gain-of-function not only prevents the normal injury-induced LAMP2A induction, but shifts the response toward an overall loss of CMA capacity during remodeling. One possible contributor to the discrepancy across datasets is the \u003cem\u003eNlrp3\u003c/em\u003e heterozygous background, which may alter baseline stress signaling and the magnitude/timing of compensatory programs. Alternatively, LAMP2A regulation may be stage-dependent, with an early adaptive induction in controls that becomes blunted, reversed, or insufficient when inflammasome activity is chronically heightened in VSMCs. Importantly, the broader marker pattern is internally consistent: TFEB was reduced, and lysosome/autophagy markers were further diminished in \u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003eSMKI\u003c/sup\u003e arteries, supporting a net impairment of autophagy\u0026ndash;lysosome homeostasis during remodeling. Collectively, these findings support an integrated model in which VSMC NLRP3 hyperactivation couples inflammatory/pyroptotic signaling with suppression of TFEB-linked stress-adaptive clearance pathways, thereby disabling compensatory proteostasis responses, promoting VSMC dysfunction, and accelerating lesion progression and foam cell\u0026ndash;like phenotypic switching.\u003c/p\u003e \u003cp\u003eFrom a translational perspective, these results elevate VSMC NLRP3 signaling as a therapeutic target to limit both restenosis-like neointimal hyperplasia and lipid-driven VSMC phenotypic switching. Systemic inflammasome or IL-1 pathway inhibition has shown promise in inflammatory cardiovascular contexts \u003csup\u003e\u003cspan citationid=\"CR51\" class=\"CitationRef\"\u003e51\u003c/span\u003e\u003c/sup\u003e, but broad immunosuppression can increase infection risk and may not optimally suppress vessel wall\u0026ndash;localized remodeling programs. Our findings, therefore, motivate an alternative strategy: cell- or lesion-targeted inhibition of the NLRP3\u0026ndash;caspase-1\u0026ndash;GSDMD axis within the vascular wall, potentially using local delivery approaches (e.g., targeted nanoparticles) to reduce off-target effects while maximizing efficacy at the remodeling site. In addition, the tight coupling between inflammasome hyperactivation and foam-like lipid accumulation suggests that targeting VSMC inflammasome signaling may provide dual benefit\u0026mdash;restraining neointimal growth while reducing lesion lipid burden and VSMC-derived foam cell formation. Complementing inflammasome-directed approaches, our data also suggest that restoring VSMC stress-adaptive programs downstream of NLRP3\u0026mdash;particularly TFEB-mediated lysosome\u0026ndash;autophagy capacity\u0026mdash;may represent a second translational direction for vascular disease in CAPS-associated settings and cardiovascular diseases characterized by intimal hyperplasia. Given our prior evidence that TFEB activation suppresses VSMC proliferation and migration \u003csup\u003e\u003cspan citationid=\"CR21\" class=\"CitationRef\"\u003e21\u003c/span\u003e,\u003cspan citationid=\"CR48\" class=\"CitationRef\"\u003e48\u003c/span\u003e,\u003cspan citationid=\"CR49\" class=\"CitationRef\"\u003e49\u003c/span\u003e\u003c/sup\u003e, and the established role of lysosome\u0026ndash;autophagy pathways in lipid clearance and inflammation control \u003csup\u003e\u003cspan citationid=\"CR50\" class=\"CitationRef\"\u003e50\u003c/span\u003e,\u003cspan citationid=\"CR52\" class=\"CitationRef\"\u003e52\u003c/span\u003e\u003c/sup\u003e, pharmacologic or gene-based activation of TFEB in VSMCs\u0026mdash;potentially using the same lesion-targeted delivery platforms\u0026mdash;could mitigate both structural remodeling and lipid-driven phenotypic switching. Thus, combined strategies that inhibit VSMC NLRP3 effector signaling and/or boost VSMC TFEB-driven protective clearance pathways may offer a rational, vessel wall\u0026ndash;focused therapeutic framework to prevent restenosis and limit pathological VSMC plasticity.\u003c/p\u003e \u003cp\u003eThis study has limitations. First, our conclusions are based on a single injury paradigm (partial carotid ligation) under a hypercholesterolemic diet, and additional models, such as wire injury, will be needed to establish generalizability across clinically relevant forms of intimal hyperplasia. Second, although our data support a causal role for VSMC NLRP3 hyperactivation, the molecular intermediates linking VSMC inflammasome signaling to the suppression of TFEB and lysosome\u0026ndash;autophagy programs remain to be defined. Third, future studies should determine whether pharmacologic inhibition of NLRP3/GSDMD (or VSMC-targeted inhibition) can rescue lesion phenotypes in \u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003eSMKI\u003c/sup\u003e mice, and whether restoring TFEB-mediated lysosomal/autophagic capacity can blunt VSMC foam transition and lesion growth.\u003c/p\u003e \u003cp\u003eIn summary, our work establishes that VSMC-intrinsic NLRP3 hyperactivation is sufficient to drive VSMC dysfunction and accelerate intimal hyperplasia, while also promoting lipid accumulation and VSMC-to\u0026ndash;foam cell\u0026ndash;like phenotypic transition. Mechanistically, these pathological responses are accompanied by suppression of TFEB and impairment of TFEB-regulated lysosome\u0026ndash;autophagy programs, identifying defective cellular clearance and stress adaptation as an additional axis downstream of inflammasome hyperactivation. Together, these findings resolve a key mechanistic gap by directly implicating VSMCs as a causative inflammasome-active compartment during vascular remodeling and suggest that the NLRP3\u0026ndash;TFEB/lysosome pathway represents a translationally actionable target for preventing restenosis, limiting plaque progression, and restraining maladaptive VSMC phenotypic switching.\u003c/p\u003e"},{"header":"Abbreviations","content":"\u003cdiv class=\"DefinitionList\"\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eα-SMA\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eAlpha-smooth muscle actin\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eCAPS\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eCryopyrin-associated periodic syndromes\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eCVDs\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eCardiovascular diseases\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eDAMPs\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eDanger-associated molecular patterns\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eDAPI\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003e4',6-diamidino-2-phenylindole\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eGSDMD\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eGasdermin D\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eGOF\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eGain-of-function\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eH\u0026amp;E staining\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eHematoxylin and eosin staining\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eIL-1β\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eInterleukin 1-beta\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eLAMP\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eLysosome-associated membrane protein\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eMMP\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eMatrix metalloproteinase\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eNLRP3\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eNOD-like receptor pyrin domain 3\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eTFEB\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eTranscription factor EB\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eVCAM 1\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eVascular cell adhesion molecule 1\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003cdiv class=\"DefinitionListEntry\"\u003e \u003cdiv class=\"Term\"\u003eVSMCs\u003c/div\u003e \u003cdiv class=\"Description\"\u003e \u003cp\u003eVascular smooth muscle cells\u003c/p\u003e \u003c/div\u003e \u003c/div\u003e \u003c/div\u003e"},{"header":"Declarations","content":" \u003cp\u003e \u003cstrong\u003eEthical approval and consent to participate\u003c/strong\u003e \u003cp\u003eNot applicable.\u003c/p\u003e \u003ch2\u003eCompeting interests\u003c/h2\u003e \u003cp\u003eThe authors declare no competing or conflicting interests.\u003c/p\u003e \u003ch2\u003eFunding\u003c/h2\u003e \u003cp\u003eThis work was supported by grants from the National Institutes of Health (R01HL150007 and R01HL122937).\u003c/p\u003e\u003ch2\u003eAuthors' contributions\u003c/h2\u003e \u003cp\u003eX.L. and Y.Z. designed the research and wrote the manuscript; Y-T.W. performed the experiments and contributed to writing the manuscript; Y-T.W., A.K.M., and R.Z. analyzed the data; W.G., B.K.M., G.L., and P-L.L. reviewed and edited the manuscript; and all authors have read and approved the final manuscript.\u003c/p\u003e\u003ch2\u003eAcknowledgment\u003c/h2\u003e \u003cp\u003eThis work was also supported by the \u0026ldquo;New Faculty Program Award\u0026rdquo; and \u0026ldquo;Drug Discovery Institute Technique Expansion Track Award from University of Houston, and the American Heart Association (23IPA1046060, B.K.M.).\u003c/p\u003e\u003ch2\u003eAvailability of data and material\u003c/h2\u003e \u003cp\u003eThe authors declare that the data supporting the findings of this study are available within the paper.\u003c/p\u003e"},{"header":"References","content":"\u003col\u003e\u003cli\u003e\u003cspan\u003eDeglise S, Bechelli C, Allagnat F (2022) Vascular smooth muscle cells in intimal hyperplasia, an update. Front Physiol 13:1081881. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3389/fphys.2022.1081881\u003c/span\u003e\u003cspan address=\"10.3389/fphys.2022.1081881\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCizek SM, Bedri S, Talusan P, Silva N, Lee H, Stone JR (2007) Risk factors for atherosclerosis and the development of preatherosclerotic intimal hyperplasia. Cardiovasc Pathol 16:344\u0026ndash;350. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.carpath.2007.05.007\u003c/span\u003e\u003cspan address=\"10.1016/j.carpath.2007.05.007\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNusca A, Viscusi MM, Piccirillo F, De Filippis A, Nenna A, Spadaccio C, Nappi F, Chello C, Mangiacapra F, Grigioni F et al (2022) Stent Neo-Atherosclerosis: Pathophysiology, Clinical Implications, Prevention, and Therapeutic Approaches. Life (Basel) 12. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3390/life12030393\u003c/span\u003e\u003cspan address=\"10.3390/life12030393\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNewby AC, Zaltsman AB (2000) Molecular mechanisms in intimal hyperplasia. \u003cem\u003eJ Pathol\u003c/em\u003e. ;190:300\u0026ndash;309. doi: 10.1002/(SICI)1096-9896(200002)190:3\u0026lt;300::AID-PATH596\u0026gt;3.0.CO;2-I\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eCao G, Xuan X, Hu J, Zhang R, Jin H, Dong H (2022) How vascular smooth muscle cell phenotype switching contributes to vascular disease. Cell Commun Signal 20:180. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1186/s12964-022-00993-2\u003c/span\u003e\u003cspan address=\"10.1186/s12964-022-00993-2\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTang HY, Chen AQ, Zhang H, Gao XF, Kong XQ, Zhang JJ (2022) Vascular Smooth Muscle Cells Phenotypic Switching in Cardiovascular Diseases. Cells 11. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3390/cells11244060\u003c/span\u003e\u003cspan address=\"10.3390/cells11244060\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSorokin V, Vickneson K, Kofidis T, Woo CC, Lin XY, Foo R, Shanahan CM (2020) Role of Vascular Smooth Muscle Cell Plasticity and Interactions in Vessel Wall Inflammation. Front Immunol 11:599415. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3389/fimmu.2020.599415\u003c/span\u003e\u003cspan address=\"10.3389/fimmu.2020.599415\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eFu Z, Yang S, Chang X, Liu P, Wang Y (2025) Vascular smooth muscle cell metabolic reprogramming and phenotypic remodeling in atherosclerosis. Cell Death Discov. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41420-025-02932-9\u003c/span\u003e\u003cspan address=\"10.1038/s41420-025-02932-9\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eJiao X, Guo D, Li W, Li S, Shao G, Shen T, Yu X (2025) Foam cells: tracing the diverse cellular origins and their linked signaling pathways. J Transl Med 23:1382. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1186/s12967-025-07402-5\u003c/span\u003e\u003cspan address=\"10.1186/s12967-025-07402-5\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGuo H, Callaway JB, Ting JP (2015) Inflammasomes: mechanism of action, role in disease, and therapeutics. Nat Med 21:677\u0026ndash;687. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/nm.3893\u003c/span\u003e\u003cspan address=\"10.1038/nm.3893\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eAbderrazak A, Syrovets T, Couchie D, El Hadri K, Friguet B, Simmet T, Rouis M (2015) NLRP3 inflammasome: from a danger signal sensor to a regulatory node of oxidative stress and inflammatory diseases. Redox Biol 4:296\u0026ndash;307. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.redox.2015.01.008\u003c/span\u003e\u003cspan address=\"10.1016/j.redox.2015.01.008\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGonzalez-Moro A, Valencia I, Shamoon L, Sanchez-Ferrer CF, Peiro C, de la Cuesta F (2022) NLRP3 Inflammasome in Vascular Disease: A Recurrent Villain to Combat Pharmacologically. Antioxid (Basel) 11. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3390/antiox11020269\u003c/span\u003e\u003cspan address=\"10.3390/antiox11020269\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhou X, Wu Y, Ye L, Wang Y, Zhang K, Wang L, Huang Y, Wang L, Xian S, Zhang Y et al (2019) Aspirin alleviates endothelial gap junction dysfunction through inhibition of NLRP3 inflammasome activation in LPS-induced vascular injury. Acta Pharm Sin B 9:711\u0026ndash;723. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.apsb.2019.02.008\u003c/span\u003e\u003cspan address=\"10.1016/j.apsb.2019.02.008\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eKesavardhana S, Malireddi RKS, Kanneganti TD (2020) Caspases in Cell Death, Inflammation, and Pyroptosis. Annu Rev Immunol 38:567\u0026ndash;595. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1146/annurev-immunol-073119-095439\u003c/span\u003e\u003cspan address=\"10.1146/annurev-immunol-073119-095439\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHuang Y, Xu W, Zhou R (2021) NLRP3 inflammasome activation and cell death. Cell Mol Immunol 18:2114\u0026ndash;2127. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41423-021-00740-6\u003c/span\u003e\u003cspan address=\"10.1038/s41423-021-00740-6\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLu N, Cheng W, Liu D, Liu G, Cui C, Feng C, Wang X (2022) NLRP3-Mediated Inflammation in Atherosclerosis and Associated Therapeutics. Front Cell Dev Biol 10:823387. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3389/fcell.2022.823387\u003c/span\u003e\u003cspan address=\"10.3389/fcell.2022.823387\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMo B, Ding Y, Ji Q (2025) NLRP3 inflammasome in cardiovascular diseases: an update. Front Immunol 16:1550226. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3389/fimmu.2025.1550226\u003c/span\u003e\u003cspan address=\"10.3389/fimmu.2025.1550226\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWang YT, Moura AK, Zuo R, Guan Y, Lee EA, Hu JZ, Roudbari K, Wang Z, Wang M, Li PL et al (2025) Contribution of NLRP3-GSDMD axis to PDGF-BB-induced vascular smooth muscle cell phenotypic transition. Am J Physiol Cell Physiol 329:C682\u0026ndash;C698. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1152/ajpcell.00226.2025\u003c/span\u003e\u003cspan address=\"10.1152/ajpcell.00226.2025\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBrydges SD, Mueller JL, McGeough MD, Pena CA, Misaghi A, Gandhi C, Putnam CD, Boyle DL, Firestein GS, Horner AA et al (2009) Inflammasome-mediated disease animal models reveal roles for innate but not adaptive immunity. Immunity 30:875\u0026ndash;887. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.immuni.2009.05.005\u003c/span\u003e\u003cspan address=\"10.1016/j.immuni.2009.05.005\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eNam D, Ni CW, Rezvan A, Suo J, Budzyn K, Llanos A, Harrison D, Giddens D, Jo H (2009) Partial carotid ligation is a model of acutely induced disturbed flow, leading to rapid endothelial dysfunction and atherosclerosis. Am J Physiol Heart Circ Physiol 297:H1535\u0026ndash;1543. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1152/ajpheart.00510.2009\u003c/span\u003e\u003cspan address=\"10.1152/ajpheart.00510.2009\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWang YT, Li X, Chen J, McConnell BK, Chen L, Li PL, Chen Y, Zhang Y (2019) Activation of TFEB ameliorates dedifferentiation of arterial smooth muscle cells and neointima formation in mice with high-fat diet. Cell Death Dis 10:676. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41419-019-1931-4\u003c/span\u003e\u003cspan address=\"10.1038/s41419-019-1931-4\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWang YT, Moura AK, Zuo R, Zhou W, Wang Z, Roudbari K, Hu JZ, Li PL, Zhang Y, Li X (2024) Coronary Microvascular Dysfunction Is Associated With Augmented Lysosomal Signaling in Hypercholesterolemic Mice. J Am Heart Assoc 13:e037460. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1161/JAHA.124.037460\u003c/span\u003e\u003cspan address=\"10.1161/JAHA.124.037460\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWang YT, Moura AK, Zuo R, Roudbari K, Hu JZ, Khan SA, Wang Z, Shentu Y, Wang M, Li PL et al (2025) Cardiovascular dysfunction and altered lysosomal signaling in a murine model of acid sphingomyelinase deficiency. J Mol Med (Berl) 103:599\u0026ndash;617. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s00109-025-02542-z\u003c/span\u003e\u003cspan address=\"10.1007/s00109-025-02542-z\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWang YT, Moura AK, Zuo R, Wang Z, Roudbari K, Hu JZ, Wang M, Li PL, Zhang Y, Li X (2025) Defective lipid droplet biogenesis exacerbates oleic acid-induced cellular homeostasis disruption and ferroptosis in mouse cardiac endothelial cells. Cell Death Discov 11:374. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1038/s41420-025-02669-5\u003c/span\u003e\u003cspan address=\"10.1038/s41420-025-02669-5\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZuo R, Wang M, Wang YT, ShenTu Y, Moura AK, Zhou Y, Roudbari K, Hu JZ, Li PL, Hao J et al (2025) Ablation of Hepatic Asah1 Gene Disrupts Hepatic Lipid Homeostasis and Promotes Fibrotic Nonalcoholic Steatohepatitis in Mice. Am J Pathol 195:542\u0026ndash;560. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.ajpath.2024.11.003\u003c/span\u003e\u003cspan address=\"10.1016/j.ajpath.2024.11.003\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBaeza C, Ribagorda M, Maya-Lopez C, Fresno M, Sanchez-Diaz T, Pintor-Chocano A, Sanz AB, Carrasco S, Ortiz A, Sanchez-Nino MD (2024) NIK Is a Mediator of Inflammation and Intimal Hyperplasia in Endothelial Denudation-Induced Vascular Injury. Int J Mol Sci 25. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3390/ijms252111473\u003c/span\u003e\u003cspan address=\"10.3390/ijms252111473\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLuo H, Li Y, Song H, Zhao K, Li W, Hong H, Wang YT, Qi L, Zhang Y (2024) Role of EZH2-mediated epigenetic modification on vascular smooth muscle in cardiovascular diseases: A mini-review. Front Pharmacol 15:1416992. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3389/fphar.2024.1416992\u003c/span\u003e\u003cspan address=\"10.3389/fphar.2024.1416992\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eScholzen T, Gerdes J (2000) The Ki-67 protein: from the known and the unknown. J Cell Physiol 182:311\u0026ndash;322. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1002/(SICI)1097-4652(200003)182:3%3C311::AID-JCP1%3E3.0.CO;2-9\u003c/span\u003e\u003cspan address=\"10.1002/(SICI)1097-4652(200003)182:3%3C311::AID-JCP1%3E3.0.CO;2-9\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBelo VA, Guimaraes DA, Castro MM (2015) Matrix Metalloproteinase 2 as a Potential Mediator of Vascular Smooth Muscle Cell Migration and Chronic Vascular Remodeling in Hypertension. J Vasc Res 52:221\u0026ndash;231. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1159/000441621\u003c/span\u003e\u003cspan address=\"10.1159/000441621\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eSettembre C, Di Malta C, Polito VA, Garcia Arencibia M, Vetrini F, Erdin S, Erdin SU, Huynh T, Medina D, Colella P et al (2011) TFEB links autophagy to lysosomal biogenesis. Science 332:1429\u0026ndash;1433. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1126/science.1204592\u003c/span\u003e\u003cspan address=\"10.1126/science.1204592\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWang Z, Li X, Moura AK, Hu JZ, Wang YT, Zhang Y (2025) Lysosome Functions in Atherosclerosis: A Potential Therapeutic Target. Cells 14. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3390/cells14030183\u003c/span\u003e\u003cspan address=\"10.3390/cells14030183\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhang Y, Wang YT, Koka S, Zhang Y, Hussain T, Li X (2020) Simvastatin improves lysosome function via enhancing lysosome biogenesis in endothelial cells. Front Biosci (Landmark Ed) 25:283\u0026ndash;298. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.2741/4807\u003c/span\u003e\u003cspan address=\"10.2741/4807\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eHubert V, Weiss S, Rees AJ, Kain R (2022) Modulating Chaperone-Mediated Autophagy and Its Clinical Applications in Cancer. Cells 11. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3390/cells11162562\u003c/span\u003e\u003cspan address=\"10.3390/cells11162562\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBonar SL, Brydges SD, Mueller JL, McGeough MD, Pena C, Chen D, Grimston SK, Hickman-Brecks CL, Ravindran S, McAlinden A et al (2012) Constitutively activated NLRP3 inflammasome causes inflammation and abnormal skeletal development in mice. PLoS ONE 7:e35979. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1371/journal.pone.0035979\u003c/span\u003e\u003cspan address=\"10.1371/journal.pone.0035979\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eMeng G, Zhang F, Fuss I, Kitani A, Strober W (2009) A mutation in the Nlrp3 gene causing inflammasome hyperactivation potentiates Th17 cell-dominant immune responses. Immunity 30:860\u0026ndash;874. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.immuni.2009.04.012\u003c/span\u003e\u003cspan address=\"10.1016/j.immuni.2009.04.012\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWynn TA, Vannella KM (2016) Macrophages in Tissue Repair, Regeneration, and Fibrosis. Immunity 44:450\u0026ndash;462. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.immuni.2016.02.015\u003c/span\u003e\u003cspan address=\"10.1016/j.immuni.2016.02.015\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eGandolfi S, Sanouj A, Chaput B, Coste A, Sallerin B, Varin A (2024) The role of adipose tissue-derived stromal cells, macrophages and bioscaffolds in cutaneous wound repair. Biol Direct 19:85. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1186/s13062-024-00534-6\u003c/span\u003e\u003cspan address=\"10.1186/s13062-024-00534-6\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eDi C, Ji M, Li W, Liu X, Gurung R, Qin B, Ye S, Qi R (2025) Pyroptosis of Vascular Smooth Muscle Cells as a Potential New Target for Preventing Vascular Diseases. Cardiovasc Drugs Ther 39:1427\u0026ndash;1438. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1007/s10557-024-07578-w\u003c/span\u003e\u003cspan address=\"10.1007/s10557-024-07578-w\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eJi N, Qi Z, Wang Y, Yang X, Yan Z, Li M, Ge Q, Zhang J (2021) Pyroptosis: A New Regulating Mechanism in Cardiovascular Disease. J Inflamm Res 14:2647\u0026ndash;2666. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.2147/JIR.S308177\u003c/span\u003e\u003cspan address=\"10.2147/JIR.S308177\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eZhou QY, Liu W, Gong SX, Tian Y, Ma XF, Wang AP (2024) Pulmonary artery smooth muscle cell pyroptosis promotes the proliferation of PASMCs by paracrine IL\u0026ndash;1beta and IL\u0026ndash;18 in monocrotaline\u0026ndash;induced pulmonary arterial hypertensive rats. Exp Ther Med 28:394. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3892/etm.2024.12683\u003c/span\u003e\u003cspan address=\"10.3892/etm.2024.12683\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eChakraborty R, Chatterjee P, Dave JM, Ostriker AC, Greif DM, Rzucidlo EM, Martin KA (2021) Targeting smooth muscle cell phenotypic switching in vascular disease. JVS Vasc Sci 2:79\u0026ndash;94. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.jvssci.2021.04.001\u003c/span\u003e\u003cspan address=\"10.1016/j.jvssci.2021.04.001\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003ePereira VL Jr., Dobre M, Dos Santos SG, Fuzatti JS, Oliveira CR, Campos LA, Brateanu A, Baltatu OC (2017) Association between Carotid Intima Media Thickness and Heart Rate Variability in Adults at Increased Cardiovascular Risk. Front Physiol 8:248. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3389/fphys.2017.00248\u003c/span\u003e\u003cspan address=\"10.3389/fphys.2017.00248\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eTao M, Mauro CR, Yu P, Favreau JT, Nguyen B, Gaudette GR, Ozaki CK (2013) A simplified murine intimal hyperplasia model founded on a focal carotid stenosis. Am J Pathol 182:277\u0026ndash;287. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.ajpath.2012.10.002\u003c/span\u003e\u003cspan address=\"10.1016/j.ajpath.2012.10.002\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eYu Y, Cai Y, Yang F, Yang Y, Cui Z, Shi D, Bai R (2024) Vascular smooth muscle cell phenotypic switching in atherosclerosis. Heliyon 10:e37727. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1016/j.heliyon.2024.e37727\u003c/span\u003e\u003cspan address=\"10.1016/j.heliyon.2024.e37727\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eBeck-Joseph J, Tabrizian M, Lehoux S (2021) Molecular Interactions Between Vascular Smooth Muscle Cells and Macrophages in Atherosclerosis. Front Cardiovasc Med 8:737934. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3389/fcvm.2021.737934\u003c/span\u003e\u003cspan address=\"10.3389/fcvm.2021.737934\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWang R, Wu W, Li W, Huang S, Li Z, Liu R, Shan Z, Zhang C, Li W, Wang S (2018) Activation of NLRP3 Inflammasome Promotes Foam Cell Formation in Vascular Smooth Muscle Cells and Atherogenesis Via HMGB1. J Am Heart Assoc 7:e008596. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1161/JAHA.118.008596\u003c/span\u003e\u003cspan address=\"10.1161/JAHA.118.008596\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWeber K, Schilling JD (2014) Lysosomes integrate metabolic-inflammatory cross-talk in primary macrophage inflammasome activation. J Biol Chem 289:9158\u0026ndash;9171. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1074/jbc.M113.531202\u003c/span\u003e\u003cspan address=\"10.1074/jbc.M113.531202\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLi X, Zhao W, Wang Z, Moura AK, Roudbari K, Zuo R, Hu JZ, Wang YT, Li PL, Zhang Y (2025) Acid Sphingomyelinase Regulates AdipoRon-Induced Differentiation of Arterial Smooth Muscle Cells via TFEB Activation. Int J Mol Sci 26. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3390/ijms26052147\u003c/span\u003e\u003cspan address=\"10.3390/ijms26052147\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eWang YT, Chen J, Li X, Umetani M, Chen Y, Li PL, Zhang Y (2019) Contribution of transcription factor EB to adipoRon-induced inhibition of arterial smooth muscle cell proliferation and migration. Am J Physiol Cell Physiol 317:C1034\u0026ndash;C1047. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1152/ajpcell.00294.2019\u003c/span\u003e\u003cspan address=\"10.1152/ajpcell.00294.2019\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLu H, Fan Y, Qiao C, Liang W, Hu W, Zhu T, Zhang J, Chen YE (2017) TFEB inhibits endothelial cell inflammation and reduces atherosclerosis. Sci Signal 10. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1126/scisignal.aah4214\u003c/span\u003e\u003cspan address=\"10.1126/scisignal.aah4214\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eRidker PM, Everett BM, Thuren T, MacFadyen JG, Chang WH, Ballantyne C, Fonseca F, Nicolau J, Koenig W, Anker SD et al (2017) Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. N Engl J Med 377:1119\u0026ndash;1131. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.1056/NEJMoa1707914\u003c/span\u003e\u003cspan address=\"10.1056/NEJMoa1707914\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e \u003cli\u003e\u003cspan\u003eLi M, Wang Z, Wang P, Li H, Yang L (2021) TFEB: A Emerging Regulator in Lipid Homeostasis for Atherosclerosis. Front Physiol 12:639920. \u003cspan class=\"ExternalRef\"\u003e\u003cspan class=\"RefSource\"\u003e10.3389/fphys.2021.639920\u003c/span\u003e\u003cspan address=\"10.3389/fphys.2021.639920\" targettype=\"DOI\" class=\"RefTarget\"\u003e\u003c/span\u003e\u003c/span\u003e\u003c/span\u003e\u003c/li\u003e\u003c/ol\u003e"}],"fulltextSource":"","fullText":"","funders":[],"hasAdminPriorityOnWorkflow":false,"hasManuscriptDocX":true,"hasOptedInToPreprint":true,"hasPassedJournalQc":"","hasAnyPriority":false,"hideJournal":false,"highlight":"","institution":"","isAcceptedByJournal":false,"isAuthorSuppliedPdf":false,"isDeskRejected":"","isHiddenFromSearch":false,"isInQc":false,"isInWorkflow":false,"isPdf":false,"isPdfUpToDate":true,"isWithdrawnOrRetracted":false,"journal":{"display":true,"email":"[email protected]","identity":"journal-of-molecular-medicine","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"jmme","sideBox":"Learn more about [Journal of Molecular Medicine](https://www.springer.com/journal/109)","snPcode":"109","submissionUrl":"https://submission.nature.com/new-submission/109/3","title":"Journal of Molecular Medicine","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"Springer Hybrid","inReviewEnabled":true,"inReviewRevisionsEnabled":false},"keywords":"VSMC, NLRP3 inflammasome, GSDMD, TFEB, lysosome–autophagy, intimal hyperplasia","lastPublishedDoi":"10.21203/rs.3.rs-8734377/v1","lastPublishedDoiUrl":"https://doi.org/10.21203/rs.3.rs-8734377/v1","license":{"name":"CC BY 4.0","url":"https://creativecommons.org/licenses/by/4.0/"},"manuscriptAbstract":"\u003cp\u003eIntimal hyperplasia is a major contributor to restenosis after vascular interventions and to atherosclerotic lesion progression, driven largely by vascular smooth muscle cell (VSMC) inflammatory activation, phenotypic switching, and maladaptive remodeling. While NOD-like receptor pyrin domain 3 (NLRP3) inflammasome activity has been linked to vascular diseases, direct evidence that VSMC-intrinsic NLRP3 hyperactivation drives VSMC dysfunction and intimal hyperplasia in vivo has been lacking. Here, we generated a VSMC-specific \u003cem\u003eNlrp3\u003c/em\u003e knock-in mouse (\u003cem\u003eNlrp3\u003c/em\u003e \u003csup\u003eL351P/+/Myh11\u0026minus;Cre\u003c/sup\u003e, \u0026ldquo;\u003cem\u003eNlrp3\u003c/em\u003e\u003csup\u003eSMKI\u003c/sup\u003e\u0026rdquo;) and subjected it to carotid partial ligation under hypercholesterolemic conditions. VSMC \u003cem\u003eNlrp3\u003c/em\u003e gain-of-function knock-in induced robust caspase-1 activation in vivo, including in unligated arteries, and markedly amplified injury-triggered inflammasome activation. \u003cem\u003eNlrp3\u003c/em\u003e\u003csup\u003eSMKI\u003c/sup\u003e arteries exhibited heightened vascular inflammation (VCAM-1 upregulation and increased macrophage accumulation), enhanced activation of Gasdermin D (GSDMD) with increased cell death, and greater VSMC proliferative/migratory remodeling. These changes translated into significantly worsened neointimal lesion growth (increased intimal area and intima-to-media ratio). Interestingly, VSMC \u003cem\u003eNlrp3\u003c/em\u003e gain-of-function accelerated vascular injury-induced lipid loading and VSMC-to-foam cell-like transition. Mechanistically, these pathological responses were accompanied by suppression of the transcription factor EB (TFEB) and broad impairment of lysosome\u0026ndash;autophagy homeostasis, supporting TFEB-dependent lysosome\u0026ndash;autophagy quality control as a central protective node that restrains not only lipid accumulation and foam cell transition, but also inflammatory activation, cell death, and proliferative/migratory remodeling during vascular injury. Collectively, these data provide the first direct evidence that VSMC NLRP3 hyperactivation drives VSMC dysfunction, intimal hyperplasia, and foam cell\u0026ndash;like phenotypic switching, highlighting VSMC NLRP3\u0026ndash;TFEB signaling as a highly translational therapeutic axis to limit restenosis and plaque progression.\u003c/p\u003e","manuscriptTitle":"Vascular Smooth Muscle–Specific NLRP3 Hyperactivation Drives Arterial Intimal Hyperplasia in Mice","msid":"","msnumber":"","nonDraftVersions":[{"code":1,"date":"2026-02-11 19:07:01","doi":"10.21203/rs.3.rs-8734377/v1","editorialEvents":[{"type":"communityComments","content":0},{"type":"decision","content":"Major Revisions Needed","date":"2026-03-13T04:08:59+00:00","index":"","fulltext":""},{"type":"reviewerAgreed","content":"","date":"2026-02-10T15:14:36+00:00","index":0,"fulltext":""},{"type":"reviewersInvited","content":"","date":"2026-02-09T14:40:00+00:00","index":"","fulltext":""},{"type":"editorAssigned","content":"","date":"2026-01-30T12:45:51+00:00","index":"","fulltext":""},{"type":"submitted","content":"Journal of Molecular Medicine","date":"2026-01-29T13:13:30+00:00","index":"","fulltext":""}],"status":"published","journal":{"display":true,"email":"[email protected]","identity":"journal-of-molecular-medicine","isNatureJournal":false,"hasQc":true,"allowDirectSubmit":false,"externalIdentity":"jmme","sideBox":"Learn more about [Journal of Molecular Medicine](https://www.springer.com/journal/109)","snPcode":"109","submissionUrl":"https://submission.nature.com/new-submission/109/3","title":"Journal of Molecular Medicine","twitterHandle":"","acdcEnabled":true,"dfaEnabled":true,"editorialSystem":"em","reportingPortfolio":"Springer Hybrid","inReviewEnabled":true,"inReviewRevisionsEnabled":false}}],"origin":"","ownerIdentity":"5b46f717-dd95-492f-b235-25460f1f38e3","owner":[],"postedDate":"February 11th, 2026","published":true,"recentEditorialEvents":[],"rejectedJournal":[],"revision":"","amendment":"","status":"in-revision","subjectAreas":[],"tags":[],"updatedAt":"2026-03-13T08:12:32+00:00","versionOfRecord":[],"versionCreatedAt":"2026-02-11 19:07:01","video":"","vorDoi":"","vorDoiUrl":"","workflowStages":[]},"version":"v1","identity":"rs-8734377","journalConfig":"researchsquare"},"__N_SSP":true},"page":"/article/[identity]/[[...version]]","query":{"redirect":"/article/rs-8734377","identity":"rs-8734377","version":["v1"]},"buildId":"XKTyCvWXoU3ODBz1xrDgd","isFallback":false,"isExperimentalCompile":false,"dynamicIds":[84888],"gssp":true,"scriptLoader":[]}